|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Sno | WO number | Year of filing | formula | claims | diseases | compounds |
| 1 | **WO2022190030** | 2022 |  | I Claim:  1. A composition comprising: zinc salt, dexpanthenol or a salt or a hydrate or a solvate thereof, said composition being formulated as a topical formulation.  2. A composition comprising zinc salt, dexpanthenol, formula II or a salt or a hydrate or a solvate thereof, said composition being formulated as a topical formulation.  3. The composition as claimed in claim 1 , wherein the zinc salt is selected from zinc oxide or zinc sulfate.  4. The composition as claimed in claim 2, wherein the formula II is selected from dilaurylglycerylfumarate, dicaprylglycerylfumarate or dilaurylglyceryl succinate.  5. A composition comprising zinc salt, dexpanthenol, cysteamine or a salt or a hydrate or a solvate thereof, said composition being formulated as a topical formulation.  6. The composition as claimed in claim 5, wherein the zinc salt is selected from zinc oxide or zinc sulfate.  7. A composition comprising zinc salt, dexpanthenol, cysteamine a salt or a hydrate or a solvate, formula II or a salt or a hydrate or a solvate thereof, said composition being formulated as a topical formulation.  8. The composition as claimed in claim 7, wherein the zinc salt is selected from zinc oxide or zinc sulfate.  9. The composition as claimed in claim 7, wherein the formula II is selected from dilaurylglycerylfumarate, dicaprylglycerylfumarate or dilaurylglyceryl succinate.  10. The composition as claimed in claim 1, claim 2, claim 5, claim 7, wherein the composition further comprises an active agent selected from the group comprising: a topical antibacterial agent, immunosuppressant, PDE inhibitors, JAK Inhibitor, sun blocks, sunscreen, essential oils, a topical antifungal agent, a topical steroid, vitamin or derivative thereof, an amino acid or derivative thereof, a fatty acid or derivative thereof and combinations thereof.  11. The composition as claimed in claim 1, claim 2, claim 5, claim 7, wherein the composition further comprises an excipient.  12. The composition as claimed in claim 11, wherein the excipient is selected from any or a combination of a diluent, an emollient, a humectant, a preservative, a solvent, natural oils, essential oils, a fragrance, an emulsifier, a preservative, an antioxidant, a penetration enhancer a fatty acid or derivative thereof, an amino acid or metabolite or derivative thereof, a surfactant, a solubilizer and a stabilizer or a combination thereof.  13. The composition as claimed in claim 1, wherein the composition is formulated as a topical cream, lotion, solution, gel, ointment, emulsion, spray formulation.  14. The composition as claimed in claim 12, wherein the emollient is selected from white petrolatum, mineral oil, isopropyl myristate, cetyl alcohol, beeswax, paraffin wax, cetomacrogol, sumac wax, shea butter and combinations thereof.  15. The composition as claimed in claim 12, wherein the humectant is selected from glycerin, glycerol, propylene glycol, butylene glycol, sorbitol, polyethylene glycol, coconut oil, olive oil, jojoba oil, castor oil and combinations thereof.  16. The composition as claimed in claim 12, wherein the surfactant is selected from Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, Span 20, Span 40, Span 60, Span 80, Tween 60, lauramide DEA, cocamide DEA, cocamide MEA, Kolliphor 20, Kolliphor 40, Kolliphor 60, Kolliphor 80, glyceryl monostearate, stearic acid, polyethylene glycol ether of cetearyl alcohol, cetostearyl alcohol, lauroyl polyoxyl-32 glycerides, fatty alcohols, glycerol monooleate, glyceryl monostearate, emulsifying wax and combinations thereof.  17. The composition as claimed in claim 12, wherein the stabilizer is propylene glycol.  18. The composition as claimed in claim 12, wherein the composition further comprises of a emulsifier for improving the homogeneity of the composition wherein the emulsifier is selected from polawax and GMS 40.  19. The composition as claimed in claim 12, wherein the composition further comprises a preservative wherein the preservative is selected from methyl paraben, propyl paraben, p-  hydroxybenzoic acid esters, quaternary ammonium compounds such as benzalkonium chloride, sodium benzoate, benzyl alcohol, butanol, ethanol and isopropyl alcohol..  20. The composition as claimed in claim 7, wherein the composition further comprises an antioxidant wherein the antioxidant is selected from anti- oxidants useful in the compositions of the present disclosure include sodium metabisulfite, vitamin A, tocopherol, ascorbic acid, tartaric acid, retinyl palmitate, sesamol, Butylated Hydroxy Anisole (BHA) and Butylated Hydroxyl Toluene (BHT). .  21. The composition as claimed in claim 7, wherein the composition further comprises a skin penetration enhancer wherein the penetration enhancer is selected from sulphoxides such as dimethylsulphoxide, DMSO, azones, laurocapram, pyrrolidones, 2-pyrrolidone, alcohols, alkanols , ethanol, decanol, glycols, propylene glycol.  22. The composition as claimed in claim 10, wherein the active agent is selected from corticosteroids, hydrocortisone, hydroxyltriamcinolone, alphamethyl, dexamethasone, dexamethasone-phosphate, beclomethasone, cysteamine hydrochloride, calamine, dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone, diacetate, diflucortolone, valerate, fluadrenolone, fluclarolone, acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine, butylester, fluocortolone, fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylpredmsolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone, diacetate, fluradrenalone, acetonide, medrysone, amciafel, amcinafide, betamethasone, chlorprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone, valerate, hydrocortisone cyclopentylproprionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, betamethasone dipropionate, triamcinolone, miconazole, econazole, ketoconazole, sertaconazole, itraconazole, voriconazole, clioquinol, bifoconazole, terconazole, butoconazole, tioconazole, oxiconazole, saperconazole, clotrimazole, haloprogin, butenafme, tolnaftate, nystatin, amorolfme, naftifme, griseofulvin, azathioprme, mycophenolic acid, leflunomide, teriflunomide, ciclosporin, pimecrolimus, tacrolimus, voclosporin, lenalidomide, pomalidomide, thalidomide, apremilast, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, baricitinib, blisibimod, nilotinib, filgotinib, tofacitmib, upadacitinib, abatacept, belatacept, etanercept pegsunercept, aflibercept, alefacept, rilonacept, apremilast, arofylline, atizoram, benafentrine, catramilast, CC-1088, CDP-840, CGH-2466, cilomilast, cipamfylline, crisaborole, denbutylline, difamilast, drotaverine, etazolate, filaminast, glaucine, HT-0712, ICI-63197 indimilast, irsogladine, lavamilast, lirimilast, lotamilast, luteolin, mesembrenone, mesembrine, mesopram, oglemilast, piclamilast, pumafentrine, revamilast, Ro 20-1724, roflumilast, rolipram, ronomilast, RPL-554, RS-25344, tetomilast, tofimilast, YM-976, zardaverine, ibudilast, roflumilast, adibendan, amrinone (inamrinone), anagrelide, benafentrine, bucladesine, carbazeran, cilostamide, cilostazol, enoximone, imazodan, KMUP-1 , menbendan, milrinone, olprinone, parogrelil , pimobendan, pumafentrine , quazinone, RPL-554, siguazodan, trequinsin, vesnarinone, zardaverine, acetildenafil, aildenafil, avanafil, beminafil, benzamidenafil, dasantafil, icariin, gisadenafil, homosildenafil, lodenafil, mirodenafil, MY-5445, Nitrosoprodenafil, Norcarbodenafil, SCH-51866, Sildenafil, Sulfoaildenafil, T-0156, Tadalafil, Udenafil, Vardenafil, abrocitinib, baricitinib, filgotinib, momelotimb, oclacitmib, peficitmib, ruxolitimb, tofacitmib, tasocitmib, CP-690550, upadacitinib, atiprimod, AZD-1480, baricitinib, chz868, cucurbitacin i (elatencin B, JSI-124) CYT387 lestaurtinib, NSC-7908, NSC-33994, pacritimb, peficitinib, ruxolitinib, SD-1008, cercosporamide, decernotinib (VX-509), peficitinib, TCS-21311, WHI-P 15 ZM-39923, ZM-449829, p-Aminobenzoic acid, Padimate O, phenylbenzimidazole sulfonic acid, cinoxate, dioxybenzone, oxybenzone, homosalate, menthyl anthramlate, octocrylene, octyl methoxycinnamate, octyl salicylate, sulisobenzone, trolamine salicylate, avobenzone, ecamsule, titanium dioxide, vitamin A and their derivatives retinol, retmaldehyde, retinyl esters, oxoretinoids, retinyl palmitate and retinyl acetate, vitamin C and their derivatives L-ascorbic acid, ascorbyl palmitate, and magnesium ascorbyl phosphate, Vitamin B3/Niacinamide and their derivatives, vitamin B-5 /pantothenic acid and their derivatives, Vitamin E / a-tocopherol and their derivatives, Vitamin K/phytonadione and their derivatives,, calciferols and their derivatives, nor-leucme, nor-valine, L-alloisoleucine, L-threoisolucine D, L, or DL-leucine-containing di- and tri-peptides, D,L, or DL- valine-containing di- and tri-peptides, D,L, or DL-isoleucine-containing di- and tri-peptides, nitrogen-free analogues of branched chain amino acids, branched chain alpha-keto acids, isovaleryl-CoA, isovalerylcarnitine, isovaleryglycine, isovaleric acid, beta-methylcrotonyl-CoA, beta-methylcrotonylcarnitine, beta-  methylcrotonylglycine, beta-methylcrotonic acid, beta- methylglutaconyl-CoA, beta- methylglutaconylcarnitine, beta-methylglutaconylglycine, beta- methylglutaconic acid,beta- hydroxy-beta-methylglutaryl-CoA, beta-hydroxy-beta- methylglutarylcarnitine, beta- hydroxy-beta-methylglutarylglycine, beta-hydroxy-beta- methylglutaric acid, acetyl-CoA, acetylcarnitine, acetylglycine, acetoacetyl-CoA, acetoacetylcarnitine, acetoacetylglycine, isobutyryl-CoA, isobutyrylcarnitme, isobutyrylglycine, isobutyric acid, methylacrylyl-CoA, methylacrylylcarnitine, methylacrylylglycine, methylacrylic acid, beta-hydroxyisobutyryl- CoA, beta-hydroxyisobutyrylcamitine, beta- hydroxyisobutyrylglycine, beta- hydroxyisobutyric acid, methylmalonate semialdehyde, propionyl-CoA, propionylcarnitine, propionylglycine, propionic acid, D-methylmalonyl-CoA, L- methylmalonyl-CoA,  DL-methylmalonyl-CoA, D-methylmalonylcarnitine, L- methylmalonylcarnitine, DL-methylmalonylcarnitine, D-methylmalonylglycine, L- methylmalonylglycine, DL-methylmalonylglycine, methylmalonic acid, succinyl-CoA, succinylcarnitine, succinylglycine, succinic acid, alpha-methylbutyryl-CoA, alpha- methylbutyrylcarnitine, alpha-methylbutyrylglycine, alpha-methylbutyric acid, tiglyl-CoA, tiglylcarnitme, tiglylglycme, tiglic acid, alpha-methyl-beta-hydroxybutyryl-CoA, alpha- methyl- beta-hydroxybutyrylcarnitine, alpha-methyl-beta-hydroxybutyrylglycine, alpha- methyl-beta- hydroxybutyric acid, alpha-methylacetoacetyl-CoA, alpha- methylacetoacetylcarnitine, alpha- methylacetoacetylglycine, alpha-methylacetoacetic acid, and combinations thereof.  23. A method of treating a skin condition in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the composition of any of the preceding claims.  24. Use of the pharmaceutical composition of any of the preceding claims in preparation of a medicament for the treatment of a skin condition in patient in need thereof. | utility in treatment of rashes and skin conditions/diseases |  |
| 2 | **WO2022175829** | 2022 |  | 1. A pharmaceutical composition comprising:  HI antagonist or a salt or a hydrate or a solvate thereof in an amount ranging from 0.001% to 10% w/w;  a diluent in an amount ranging from 30% to 80% w/w;  a solvent/co-solvent in an amount ranging from 1% to 30% w/w;  an emollient in an amount ranging from 10% to 40% w/w;  a humectant in an amount ranging from 5% to 30% w/w;  a preservative in an amount ranging from 0.1 % to 15% w/w;  an emulsifier in an amount ranging from 0.1 % to 10% w/w; and  a surfactant in an amount ranging from 2% to 30% w/w,  said composition being formulated as a topical formulation.  2. The composition as claimed in claim 1, wherein the HI antagonist is selected from fexofenadine, diphenhydramine , cetirizine, levocetirizine, montelukast or a combination thereof.  3. The composition as claimed in claim 1, wherein the composition is aqueous or non-aqueous composition.  4. The composition as claimed in claim3, wherein the composition is aqueous composition the diluent is water.  5. The composition as claimed in claim 1, wherein the solvent/co-solvents is selected from ethanol, butylene glycol, propylene glycol, isopropyl alcohol, isoprene glycol, benzyl alcohol, cremophor EL and combinations thereof.  6. The composition as claimed in claim 1 , wherein the solvent comprises benzyl alcohol.  7. The composition as claimed in claim 1, wherein the preservative is selected from benzyl alcohol, germaben II, propylene glycol, diazolidinyl urea, methylparaben, propylparaben, BKC, Zinc salts, phenoxyethano 1, imidazolidinyl urea, sorbic acid, benzoic acid, sodium benzoate and combination thereof.  8. The composition as claimed in claim 1, wherein the emollient is selected from white petrolatum, light mineral oil, heavy mineral oil, isopropyl myristate, cetyl alcohol and combinations thereof.  9. The composition as claimed in claim 1, wherein the humectant is selected from glycerin, glycerol, propylene glycol, butylene glycol, sorbitol, polyethylene glycol and combinations thereof.  10. The composition as claimed in claim 1, wherein the surfactant, is selected from Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, Span 20, Span 40, Span 60, Span 80, lauramide DEA, TEA, IPM, cocamide DEA, cocamide ME A, glyceryl monostearate, stearic acid, polyethylene glycol ether of cetearyl alcohol, lauroyl polyoxyl-32 glycerides, fatty acid derivatives and combinations thereof.  11. The composition as claimed in claim 1, wherein the emulsifier is selected from cetostearyl alcohol 50, ceteareth 20, polyoxyl cetostearyl ethers, cetyl alcohol, lauroyl polyoxyl-32 glycerides, stearyl alcohol, and combinations thereof.  12. The composition as claimed in claim 1, wherein the composition further comprises a skin penetration enhancer in an amount ranging from 0.01% to 10% w/w.  13. The composition as claimed in claim 1, wherein the composition further comprises a pharmaceutical agent selected from the group comprising: a corticosteroid, HI antagonist, a PDE inhibitor, JAK inhibitor, NO releasing drug, an anti-inflammatory agent, an immunosuppressant, an antibiotic, an antifungal agent, a non-steroidal anti-inflammatory agent, a retinoid agent, an antipruritic agent, sun block agent and a keratolytic agent.  14. The composition as claimed in claim 1, wherein the composition is formulated as a solution, spray, lotion, cream, gel, ointment, or as an emulsion, oil in water emulsion, water in oil emulsion for topical, dermal or transdermal administration.  15. A composition for topical treatment of allergic condition comprising: HI antihistamine or a salt or a hydrate or a solvate thereof, a diluent, a solvent, an emollient, a humectant, a emulsifier, preservative, stabilizer, surfactant and one or more additional excipients; wherein the allergic condition is atopic contact dermatitis, eczema, urticaria, psoriasis, angioedema, hereditary angiodema or the combination thereof.  16. A method of treating an allergic condition, in a patient in need thereof comprising applying to a subject a therapeutically effective amount of the composition as claimed in claim 1 , wherein the allergic condition is atopic contact dermatitis, eczema, urticaria, psoriasis, angioedema, hereditary angiodema or the combination thereof.  17. The method as claimed in claim 15, wherein the composition comprises a topical solution, spray, lotion, gel, topical emulsion, cream or ointment.  18. Use of the pharmaceutical composition as claimed in claim 1, in preparation of a medicament for the treatment of the allergic condition. | treatment of allergic conditions/diseases of skin |  |
| 3 | **US20220233629** | 2022 |  | |  | | --- | | **1**. A composition comprising: lidocaine, or a salt or a hydrate or a solvate thereof; L-Carnosine, or a salt or a hydrate or a solvate thereof; and dexpanthenol, or a salt or a hydrate or a solvate thereof; wherein said composition is formulated as an oral formulation. | | **2**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises lidocaine, or a salt or a hydrate or a solvate thereof; L-Carnosine, or a salt or a hydrate or a solvate thereof; and dexpanthenol; or a salt or a hydrate or a solvate thereof; in a weight ratio ranging from 1:1:1 to 7:1:20. | | **3**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises, or a salt or a hydrate or a solvate thereof; L-Carnosine, or a salt or a hydrate or a solvate thereof; and dexpanthenol; or a salt or a hydrate or solvate thereof; in a weight ratio ranging from 1:1:1 to 5:1:10. | | **4**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition further comprises at least one excipient. | | **5**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition further comprises at least one other active agent. | | **6**. The composition as claimed in [**claim 4**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00004), wherein the at least one excipient is selected from a group consisting of a diluent, an antioxidant, a preservative, a solvent, a flavoring agent, a sweetener, a fatty acid or derivative thereof, an amino acid or metabolite or derivative thereof, a vitamin, a surfactant, a solubilizer, a stabilizer, and any combination thereof. | | **7**. The composition as claimed in [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00005), wherein the at least one other active agent is selected from a group consisting of benzocaine, clonidine, bupivacaine, ropivacaine, mepivacaine, morphine, fentanyl, orthoform, levo-bupivacaine, bibucaine, prilocaine, acetaminophen, procaine, diphenhydramine, polaprezinc, benzydamine, pentoxifylline, ortetracaine, ketamine, misoprostol, amifostine, palifermin, chlorhexidine gluconate, dusquetide, melatonin, indraline, androstenetriol, actovegin, rebamipide, EC-18, brilacidin, validive, streptomycin, kanamycin, neomycin, gentamicin, betamethasone, betamethasone esters, clobetasol, clobetasol propionate, clobetasone, clocortolone, clocortolone esters, dexamethasone, dexamethasone esters, diflorasone, diflucortolone, diflucortolone valerate, fluclorolone, flumetasone, fluocortin, fluocortolone, fluocortolone esters, fluprednidene acetate, fluticasone, fluticasone furoate, fluticasone propionate, halometasone, meprednisone, mometasone, mometasone furoate, triamcinolone, ulobetasol (halobetasol), 2-mercaptoethane sodium sulphonate, 2-Mercaptoethylguanidine, methylprednisolone, beclomethasone dipropionate, fluocinonide, clobetasol, betamethasone sodium phosphate, prednisolone, colchicine, azathioprine, thalidomide, dapsone, mycophenolate mofetil, adalimumab, clofazimine, levamisole, hydrocortisone sodium succinate, montelukast, triamcinolone, sulodexide, α-Lipoic acid, cysteamine, folic acid, hydrolytic enzyme, mucotrol, polaprezinc, traumeel, tretinoin, vitamins (calcipotriene, calcitriol, ergosterol, 1α-hydroxycholecalciferol, vitamin D2, vitamin D3, ascorbic acid, calcium ascorbate, nicotinamide ascorbate, sodium ascorbate, α-carotene, β-carotene, δ-carotene, vitamin A, cobamamide, folic acid, hydroxocobalamin, sodium folate, vitamin B12, menadiol, menadione, menadoxime, menaquinones, phylloquinone, vitamin K5, inositol, α-tocopherol, γ-tocopherol, vitamin E, zinc, selenium, potassium, copper, manganese, copper, aluminum, zinc sulfate, magnesium, magnesium aluminum hydroxide, magnesium sulfate, calcium phosphate, magnesium stearate, magnesium silicate, magnesium sulphate, magnesium chloride, magnesium bromide, magnesium acetate, magnesium lactate, magnesium pidolate, magnesium thiosulphate, magnesium sulphate, Cu2+ salts such as copper sulfate pentahydrate, copper sulfate, copper malonate, copper citrate, copper oxalate, copper tartarate, copper lactate, copper chloride, copper bromide, copper pidolate, copper phosphate, copper nitrate, copper thiosulphate, Al+3 salts such as aluminum oxide, aluminum palmitate, aluminum stearate, aluminum chloride, aluminum oxychloride, aluminum barium silicate, Aluminum magnesium hydroxide stearate, aluminum propionate aluminum dipropionate, aluminum aceto propionate, aluminum citro propionate, aluminum lacto propionate, aluminum tartaro propionate, aluminum acetodipropionate, aluminum citrodipropionate, aluminum lacto dipropionate, and aluminum tartarodipropionate and the likes, Polymers such as carbomer, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, chitosan sulfate, ethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, carboxy methyl cellulose, polyethylene oxide, chitosan pyrrolidone carboxylate, amphotericin B, benzoxonium chloride, chlorhexidine, chlortetracycline, clotrimazole, cetylpyridinium chloride, domiphen bromide, amoxicillin, cephalexin, ciprofloxacin, clindamycin, azithromycin, sulfamethoxazole, trimethoprim, clavulanate, levofloxacin, doxycycline, eugenol, hexetidine, hydrogen peroxide, mepartricin, metronidazole, miconazole, minocycline, natamycin, neomycin, oxyquinoline, polynoxylin, sodium perborate, tetracycline, tibezonium iodide, amlexanox, acetylsalicylic acid, becaplermin, benzydamine, epinephrine/adrenalone, fluocinonide, tetracycline, minocycline, chlorhexidine gluconate, triclosan, azathioprine, mycophenolic acid, cyclosporines, leflunomide, teriflunomide, ciclosporin, pimecrolimus, tacrolimus, voclosporin, lenalidomide, pomalidomide, thalidomide, apremilast, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, baricitinib, blisibimod, nilotinib, filgotinib, tofacitinib, upadacitinib, abatacept, belatacept, etanercept, pegsunercept, amlexanox, aflibercept, alefacept, rilonacept, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate, isoamyl nitrite, derivatives and analogs with the NO releasing properties, apremilast, arofylline, atizoram, benafentrine, catramilast, CC-1088, CDP-840, CGH-2466, cilomilast, cipamfylline, crisaborole, denbutylline, difamilast, drotaverine, etazolate, filaminast, glaucine, HT-0712, ICI-63197 indimilast, irsogladine, lavamilast, lirimilast, lotamilast, luteolin, mesembrenone, mesembrine, mesopram, oglemilast, piclamilast, pumafentrine, revamilast Ro 20-1724, roflumilast, rolipram, ronomilast, RPL-554, RS-25344, tetomilast, tofimilast, YM-976, zardaverine, ibudilast, roflumilas, adibendan, amrinone (inamrinone), anagrelide, benafentrine, bucladesine, carbazeran, cilostamide, cilostazol, enoximone, imazodan, KMUP-1, meribendan, milrinone, olprinone, parogrelil, pimobendan, pumafentrine, quazinone, RPL-554, siguazodan, trequinsin, vesnarinone, zardaverine; pde 5 inhibitors such as acetildenafil, aildenafil, avanafil, beminafil, benzamidenafil, dasantafil, icariin, gisadenafil, homosildenafil, lodenafil, mirodenafil, MY-5445, nitrosoprodenafil, norcarbodenafil, SCH-51866, sildenafil, sulfoaildenafil, T-0156, tadalafil, udenafil, vardenafil, abrocitinib, baricitinib, filgotinib, momelotinib, oclacitinib, peficitinib, ruxolitinib, tofacitinib, tasocitinib, CP-690550, upadacitinib, atiprimod, AZD-1480, baricitinib, CHZ868, cucurbitacin I (elatericin B, JSI-124), CYT387, lestaurtinib, NSC-7908, NSC-33994, pacritinib, peficitinib, ruxolitinib, SD-1008, cercosporamide, decernotinib (VX-509), peficitinib, TCS-21311, WHI-P 15 ZM-39923, ZM-449829, methotrexate, ciclosporin, diclofenac, indomethacin, sulindac, mefenamic acid, piroxicam, ibuprofen, ketoprofen, naproxen, phenylbutazone, meloxicam, nimesulide, celecoxib, etoricoxib WBI-1001, MRX-6, valdecoxib, other derivatives thereof, analogs thereof, and any mixture thereof. | | **8**. The composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00006), wherein the fatty acid derivative is selected from a group consisting of diglyceryl lauryl fumarate, diglyceryl lauryl succinate, diglyceryl capryl succinate, and any combination thereof. | | **9**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition is formulated as an oral rinse formulation. | | **10**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises  lidocaine or a salt or a hydrate or a solvate thereof in an amount ranging from 0.25% w/v to 10% w/v;  L-Carnosine or a salt or a hydrate or a solvate thereof in an amount ranging from 0.25% w/v to 5% w/v;  dexpanthenol or a salt or a hydrate or a solvate thereof in an amount ranging from 0.5% w/v to 25% w/v;  a polyhydric alcohol in an amount ranging from 5% w/v to 30% w/v;  an anti-oxidant in an amount ranging from 0.01% w/v to 3% w/v;  a buffer in an amount ranging from 0.02% w/v to 5% w/v;  a surfactant in an amount ranging from 1% w/v to 30% w/v;  a sweetener in an amount ranging from 0.5% w/v to 25% w/v;  a preservative in an amount ranging from 0.01% w/v to 5% w/v; and  water in an amount ranging from 35% w/v to 90% w/v. | | **11**. The composition of [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the polyhydric alcohol is selected from the group consisting of polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and mixtures thereof. | | **12**. The composition of [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the antioxidant is selected from group consisting of sodium metabisulfite, vitamin A, tocopherol, ascorbic acid or salt or derivative thereof, tartaric acid or salt or derivative thereof, retinyl palmitate, sesamol, thiol derivatives, butylated hydroxy anisole (BHA), butylated hydroxyl toluene (BHT), and mixtures thereof. | | **13**. The composition as claimed in [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the buffer is selected from the group consisting of citric acid or salt or derivative thereof, benzoic acid or salt or derivative thereof, sorbic acid or salt or derivative thereof, succinic acid or salt or derivative thereof, and mixtures thereof. | | **14**. The composition as claimed in [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the sweetener is selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and mixtures thereof. | | **15**. The composition of [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the composition further comprises hyaluronic acid, or a salt or derivative thereof, in an amount ranging from 0.02% w/v to 15% w/v. | | **16**. The composition as [**claim 9**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00009), wherein the composition has a pH ranging from 4.5 to 7.5. | | **17**. A method of treating oral, pharyngeal, oropharyngeal and esophageal conditions in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001). | | **18**. Use of the pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001) in preparation of a medicament for the treatment of oral, pharyngeal, oropharyngeal and esophageal diseases or conditions in patient in need thereof. | | **19**. A method for manufacturing the composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126802&_cid=P12-L949Q3-32596-1#CLM-00001) comprising the steps of:  a. preparing a premix 1 in a compounding vessel by adding D-panthenol and water and mixing with an overhead stirrer or equivalent;  b. preparing a premix 2 in a second compounding vessel by adding water, citric acid anhydrous, tri sodium citrate dihydrate, local anesthetic, one or more other agents, L-carnosine, xylitol powder 90, propylene glycol, sodium metabisulfite, benzalkonium chloride, glycerol, PVP K30 and stirred using magnetic stirrer or equivalent to get a clear solution;  c. preparing a premix 3 in a third compounding vessel by adding sodium hyaluronate and water and mixing with the overhead stirrer or equivalent to get a clear viscous solution;  d. the premix 1 is added to the premix 2 and allowed to dissolve completely before adding the premix 3 and allowed to dissolve completely; and  e. the final volume of the composition from step (d) is adjusted using water. | | treatment of oral mucositis, ulcers, ulcer |  |
| 4 | **US20220233504** | 2022 |  | |  |  | | --- | --- | |  |  | | **1**. A pharmaceutical composition comprising: Lidocaine or salt or hydrates or solvates thereof and Melatonin thereof. | | | **2**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises Lidocaine or salt or hydrates or solvates thereof and Melatonin thereof in a weight ratio ranging from 1:1 to 400:1. | | | **3**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises Lidocaine or salt or hydrates or solvates thereof and Melatonin thereof in a weight ratio ranging from 5:1 to 150:1. | | | **4**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein Lidocaine or salt or hydrates or solvates thereof is present in an amount ranging from 50 mg to 400 mg. | | | **5**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein Melatonin thereof is present in an amount ranging from 1 mg to 60 mg. | | | **6**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition further comprises a pharmaceutically acceptable excipient. | | | **7**. The composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00006), wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an antifoaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or derivative thereof, a bulking agent, an antitacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer. | | | **8**. The composition of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00007), wherein the fatty acid derivative comprises any or a combination of: diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate. | | | **9**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient. | | | **10**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, wherein the intra-granular portion comprises a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin thereof and a pharmaceutically acceptable excipient. | | | **11**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, wherein the intra-granular portion comprises Melatonin thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient. | | | **12**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin thereof and a pharmaceutically acceptable excipient. | | | **13**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, and wherein the portions are compressed together to obtain any of a tablet dosage form and a Lozenge dosage form, optionally coated with a seal coat. | | | **14**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises an intragranular portion and an extra-granular portion, and wherein the intra-granular portion comprises a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg and a pharmaceutically acceptable excipient. | | | **15**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation. | | | **16**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 3 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation. | | | **17**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001), wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 200 mg, Melatonin in an amount of 3 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation. | | | **18**. A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001). | | | **19**. Use of the pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US370126546&_cid=P12-L949Q3-32596-1#CLM-00001) in preparation of a medicament for the treatment of oral and gastrointestinal diseases in patient in need thereof. | | |  |  |
| 5 | **US20220233508** | 2022 |  | 1. A pharmaceutical composition comprising: Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof.  2. The composition of claim 1, wherein the composition comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 1:1:1 to 100:400:1.  3. The composition of claim 1, wherein the composition comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 2:5:1 to 10:50:1.  4. The composition of claim 1, wherein Famotidine or salt or hydrates or solvates thereof is present in an amount ranging from 10 mg to 100 mg.  5. The composition of claim 1, wherein Lidocaine or salt or hydrates or solvates thereof is present in an amount ranging from 50 mg to 400 mg.  6. The composition of claim 1, wherein Melatonin or salt or hydrates or solvates thereof is present in an amount ranging from 1 mg to 60 mg.  7. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.  8. The composition of claim 7, wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an anti-foaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or amino acid derivatives, a bulking agent, an anti-tacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer.  9. The composition of claim 8, wherein the fatty acid derivative comprises any or a combination of diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate.  10. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  11. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  12. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  13. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  14. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the portions are compressed together to obtain any of a tablet dosage form and a Lozenge dosage form, optionally coated with a seal coat.  15. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Famotidine in an amount of 40 mg, Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  16. A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of claim 1.  17. Use of a pharmaceutical composition of claim 1 in preparation of a medicament for the treatment of oral and gastrointestinal disorders in a patient in need thereof. | treatment of oral mucositis, gastritis, gastric ulcers |  |
| 6 | **WO2022157564** | 2022 |  | 1. A pharmaceutical composition comprising: Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof.  2. The composition of claim 1, wherein the composition comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 1:1:1 to 100:400: 1.  3. The composition of claim 1, wherein the composition comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 2:5: 1 to 10:50: 1.  4. The composition of claim 1, wherein Famotidine or salt or hydrates or solvates thereof is present in an amount ranging from 10 mg to 100 mg.  5. The composition of claim 1, wherein Lidocaine or salt or hydrates or solvates thereof is present in an amount ranging from 50 mg to 400 mg.  6. The composition of claim 1 , wherein Melatonin or salt or hydrates or solvates thereof is present in an amount ranging from 1 mg to 60 mg.  7. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.  8. The composition of claim 7, wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an anti-foaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or amino acid derivatives, a bulking agent, an anti-tacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer.  The composition of claim 8, wherein the fatty acid derivative comprises any or a combination of diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  The composition of claim 1 , wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and Lidocaine or salt or hydrates or solvates thereofand a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the portions are compressed together to obtain any of a tablet dosage form and a Lozenge dosage form, optionally coated with a seal coat.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Famotidine in an amount of 40 mg, Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of any of the preceding claims.  Use of a pharmaceutical composition of any of the preceding claims in preparation of a medicament for the treatment of oral and gastrointestinal disorders in a patient in need thereof. | treatment of oral mucositis, gastritis, gastric ulcers |  |
| 7 | **WO2022157563** | 2022 |  | 1. A pharmaceutical composition comprising: Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof.  2. The composition of claim 1, wherein the composition comprises Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 1: 1 to 400: 1.  3. The composition of claim 1, wherein the composition comprises Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 5: 1 to 150: 1.  4. The composition of claim 1, wherein Lidocaine or salt or hydrates or solvates thereof is present in an amount ranging from 50 mg to 400 mg.  5. The composition of claim 1, wherein Melatonin or salt or hydrates or solvates thereof is present in an amount ranging from 1 mg to 60 mg.  6. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.  7. The composition of claim 7, wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an anti-foaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or derivative thereof, a bulking agent, an anti-tacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer.  8. The composition of claim 8, wherein the fatty acid derivative comprises any or a combination of: diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate.  9. The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1 , wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Lidocaine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the portions are compressed together to obtain any of a tablet dosage form and a Lozenge dosage form, optionally coated with a seal coat.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises a pharmaceutically acceptable excipient, and the extra-granular portion comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 10 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation.  The composition of claim 1, wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 100 mg, Melatonin in an amount of 3 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation.  The composition of claim 1, wherein the composition comprises Lidocaine hydrochloride monohydrate in an amount of 200 mg, Melatonin in an amount of 3 mg and a pharmaceutically acceptable excipient, said composition being a directly compressed lozenge formulation.  A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition of any of the preceding claims.  Use of the pharmaceutical composition of any of the preceding claims in preparation of a medicament for the treatment of oral and gastrointestinal diseases in patient in need thereof. | utility in treatment of mucositis, oral mucositis, ulcers, ulcer mediated pain and the like conditions. |  |
| 8 | **WO2022157587** | 2022 |  | A composition comprising: Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof, said composition being formulated as an oral formulation.  The composition as claimed in claim 1, wherein the composition comprises lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof in a weight ratio ranging from 1:1:1 to 7: 1 :20.  The composition as claimed in claim 1, wherein the composition comprises lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof in a weight ratio ranging from 1:1:1 to 5: 1 : 10.  The composition as claimed in claim 1 , wherein the composition further comprises an excipient.  The composition as claimed in claim 1, wherein the composition further comprises at least one other active agent.  The composition as claimed in claim 4, wherein the excipient is selected from any or a combination of: a diluent, an antioxidant, a preservative, a solvent, a flavoring agent, a sweetener, a fatty acid or derivative thereof, an amino acid or metabolite or derivative thereof, a vitamin, a surfactant, a solubilizer and a stabilizer.  The composition as claimed in claim 5, wherein the at least one other active agent is selected from benzocaine, clonidine, bupivacaine, ropivacaine, mepivacaine, morphine, fentanyl, orthoform, levo-bupivacaine, bibucaine, prilocaine, acetaminophen, procaine, diphenhydramine, polaprezinc, benzydamine, pentoxifylline, ortetracaine, ketamine, misoprostol, amifostine, palifermin, chlorhexidine gluconate, dusquetide, melatonin, indraline, androstenetriol, actovegin, rebamipide, EC- 18, brilacidin, validive, streptomycin, kanamycin, neomycin, gentamicin, betamethasone, betamethasone esters, clobetasol, clobetasol propionate, clobetasone, clocortolone, clocortolone esters, dexamethasone, dexamethasone esters, diflorasone, diflucortolone, diflucortolone valerate, fluclorolone, flumetasone, fluocortin, fluocortolone, fluocortolone esters, fluprednidene acetate, fluticasone, fluticasone furoate, fluticasone propionate, halometasone, meprednisone, mometasone, mometasone furoate, triamcinolone, ulobetasol (halobetasol), 2-mercaptoethane sodium sulphonate, 2-Mercaptoethylguanidine, methylprednisolone, beclomethasone dipropionate, fluocinonide, clobetasol, betamethasone sodium phosphate, prednisolone, colchicine, azathioprine, thalidomide, dapsone, mycophenolate mofetil, adalimumab, clofazimine, levamisole, hydrocortisone sodium succinate, montelukast, triamcinolone, sulodexide, a-Lipoic acid, cysteamine, folic acid, hydrolytic enzyme, mucotrol, polaprezinc, traumeel, tretinoin, vitamins (calcipotriene, calcitriol, ergosterol, la-hydro xycholecalciferol, vitamin D2, vitamin D3, ascorbic acid, calcium ascorbate, nicotinamide ascorbate, sodium ascorbate, a-carotene, P-carotene, 5-carotene, vitamin A, cobamamide, folic acid, hydroxocobalamin, sodium folate, vitamin B12, menadiol, menadione, menadoxime, menaquinones, phylloquinone, vitamin K5, inositol, a-tocopherol, y-tocopherol, vitamin E, zinc, selenium, potassium, copper, manganese, copper, aluminum, zinc sulfate, magnesium, magnesium aluminum hydroxide, magnesium sulfate, calcium phosphate, magnesium stearate, magnesium silicate, magnesium sulphate, magnesium chloride, magnesium bromide, magnesium acetate, magnesium lactate, magnesium pidolate, magnesium thiosulphate, magnesium sulphate, Cu2+ salts such as copper sulfate pentahydrate, copper sulfate, copper malonate, copper citrate, copper oxalate, copper tartarate, copper lactate, copper chloride, copper bromide, copper pidolate, copper phosphate, copper nitrate, copper thiosulphate, Al+3 salts such as aluminum oxide, aluminum palmitate, aluminum stearate, aluminum chloride, aluminum oxychloride, aluminum barium silicate, Aluminum magnesium hydroxide stearate, aluminum propionate aluminum dipropionate, aluminum aceto propionate, aluminum citro propionate, aluminum lacto propionate, aluminum tartaro propionate, aluminum acetodipropionate, aluminum citrodipropionate, aluminum lacto dipropionate, and aluminum tartarodipropionate and the likes, Polymers such as carbomer, methyl cellulose, sodium carboxyl methyl cellulose, carrageenan, colloidal silicon dioxide, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyethylene oxide, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, chitosan sulfate, ethyl cellulose, hydroxypropyl cellulose, hydroxymethyl cellulose, carboxy methyl cellulose, polyethylene oxide, chitosan pyrrolidone carboxylate, amphotericin B, benzoxonium chloride, chlorhexidine, chlortetracycline, clotrimazole, cetylpyridinium chloride, domiphen bromide, amoxicillin, cephalexin, ciprofloxacin, clindamycin, azithromycin, sulfamethoxazole, trimethoprim, clavulanate, levofloxacin, doxycycline, eugenol, hexetidine, hydrogen peroxide, mepartricin, metronidazole, miconazole, minocycline, natamycin, neomycin, oxyquinoline, polynoxylin, sodium perborate, tetracycline, tibezonium iodide, amlexanox, acetylsalicylic acid, becaplermin, benzydamine, epinephrine/adrenalone, fluocinonide, tetracycline, minocycline, chlorhexidine gluconate, triclosan, azathioprine, mycophenolic acid, cyclosporines, leflunomide, teriflunomide, ciclosporin, pimecrolimus, tacrolimus, voclosporin, lenalidomide, pomalidomide, thalidomide, apremilast, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, baricitinib, blisibimod, nilotinib, filgotinib, tofacitinib, upadacitinib, abatacept, belatacept, etanercept, pegsunercept, amlexanox, aflibercept, alefacept, rilonacept, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate, isoamyl nitrite, derivatives and analogs with the NO releasing properties, apremilast, arofylline, atizoram, benafentrine, catramilast, CC-1088, CDP-840, CGH-2466, cilomilast, cipamfylline, crisaborole, denbutylline, difamilast, drotaverine, etazolate, filaminast, glaucine, HT-0712, ICI-63197 indimilast, irsogladine, lavamilast, lirimilast, lotamilast, luteolin, mesembrenone, mesembrine, mesopram, oglemilast, piclamilast, pumafentrine, revamilast Ro 20-1724, roflumilast, rolipram, ronomilast, RPL-554, RS-25344, tetomilast, tofimilast, YM-976, zardaverine, ibudilast, roflumilas, adibendan, amrinone (inamrinone), anagrelide, benafentrine, bucladesine, carbazeran, cilostamide, cilostazol, enoximone, imazodan, KMUP-1, meribendan, milrinone, olprinone, parogrelil , pimobendan, pumafentrine, quazinone, RPL-554, siguazodan, trequinsin, vesnarinone, zardaverine; pde 5 inhibitors such as acetildenafil, aildenafil, avanafil, beminafil, benzamidenafil, dasantafil, icariin, gisadenafil, homosildenafil, lodenafil, mirodenafil, MY-5445, nitrosoprodenafil, norcarbodenafil, SCH-51866, sildenafil, sulfo aildenafil, T-0156, tadalafil, udenafil, vardenafil, abrocitinib, baricitinib, filgotinib, momelotinib, oclacitinib, peficitinib, ruxolitinib, tofacitinib, tasocitinib, CP-690550, upadacitinib, atiprimod, AZD-1480, baricitinib, CHZ868, cucurbitacin I (elatericin B, JSI-124), CYT387, lestaurtinib, NSC-7908, NSC-33994, pacritinib, peficitinib, ruxolitinib, SD-1008, cercosporamide, decernotinib (VX-509), peficitinib, TCS-21311, WHLP 15 ZM-39923, ZM-449829, methotrexate, ciclosporin, diclofenac, indomethacin, sulindac, mefenamic acid, piroxicam, ibuprofen, ketoprofen, naproxen, phenylbutazone, meloxicam, nimesulide, celecoxib, etoricoxib WBI-1001, MRX-6, valdecoxib and a mixture thereof.  The composition of claim 6, wherein the fatty acid derivative comprises any or a combination of: diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate.  The composition as claimed in claim 1, wherein the composition is formulated as an oral rinse formulation.  The composition as claimed in claim 1, wherein the composition comprises:  lidocaine or salt or hydrate or solvate thereof in an amount ranging from 0.25% w/v to 10% w/v;  L-Carnosine or salt or hydrate or solvate thereof in an amount ranging from 0.25% w/v to 5% w/v;  dexpanthenol or salt or hydrate or solvate thereof in an amount ranging from 0.5% w/v to 25% w/v;  a polyhydric alcohol in an amount ranging from 5% w/v to 30% w/v;  an anti-oxidant in an amount ranging from 0.01% w/v to 3% w/v;  a buffer in an amount ranging from 0.02% w/v to 5% w/v;  a surfactant in an amount ranging from 1% w/v to 30% w/v;  a sweetener in an amount ranging from 0.5% w/v to 25% w/v;  a preservative in an amount ranging from 0.01% w/v to 5% w/v; and  water in an amount ranging from 35% w/v to 90% w/v.  The composition as claimed in claim 9, wherein the polyhydric alcohol is selected from polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and mixtures thereof.  The composition as claimed in claim 9, wherein the antioxidant is selected from sodium metabisulfite, vitamin A, tocopherol, ascorbic acid or salt or derivative thereof, tartaric acid or salt or derivative thereof, retinyl palmitate, sesamol, thiol derivatives, butylated hydroxy anisole (BHA), butylated hydroxyl toluene (BHT), and mixtures thereof.  The composition as claimed in claim 9, wherein the buffer is selected from citric acid or salt or derivative thereof, benzoic acid or salt or derivative thereof, sorbic acid or salt or derivative thereof, succinic acid or salt or derivative thereof, and mixtures thereof.  The composition as claimed in claim 9, wherein the sweetener is selected from sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and mixtures thereof.  The composition as claimed in claim 9, wherein the composition further comprises hyaluronic acid or salt or derivative thereof in an amount ranging from 0.02% w/v to 15 % w/v.  The composition as claimed in claim 9, wherein the composition has a pH ranging from 4.5 to 7.5.  A method of treating oral, pharyngeal, oropharyngeal and esophageal conditions in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the composition of any of the preceding claims.  Use of the pharmaceutical composition of any of the preceding claims in preparation of a medicament for the treatment of oral, pharyngeal, oropharyngeal and esophageal diseases or conditions in patient in need thereof.  A method for manufacturing composition of claim 1 comprising the steps of:  a. preparing a premix 1 in a compounding vessel by adding D-panthenol and water and mixing with an overhead stirrer;  b. preparing premix 2 in a second compounding vessel by adding water, citric acid anhydrous, tri sodium citrate dihydrate, local anesthetic, one or more other agents, L- carnosine, xylitol powder 90, propylene glycol, sodium metabisulfite, benzalkonium chloride, glycerol, PVP K30 and stirred using magnetic stirrer to get a clear solution; c. preparing premix 3 in a third compounding vessel by adding sodium hyaluronate and water and mixing with the overhead stirrer to get a clear viscous solution;  d. premix 1 is added to the premix 2 and allowed to dissolve completely before adding premix 3 and allowed to dissolve completely; and  e. the final volume of the composition is adjusted using water. | treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions |  |
| 9 |  | 2022 |  | 1. ​A compound of Formula I:    ​and pharmaceutically acceptable hydrates, solvates, enantiomers and stereoisomers thereof for use in the treatment of xerostomia, dryness of the mouth and dryness of the mouth in the Sjogren syndrome;  ​Where,  ​RH independently represents omega 3 fatty acids, omega 6 fatty acids, alpha lipoic acid or R-lipoic acid.  2. ​A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  3. ​The pharmaceutical composition of claim 2, which is formulated to treat the underlying etiology with an effective amount administered to the patient in need thereof by oral administration, delayed release or sustained release, transmucosal, syrup, topical administration, parenteral, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration. | treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, capping, spraying, intravenous, oral solution​, buccal mucosa layer tablet, parenteral administration, syrup or injection. Said compositions can be used for the treatment of inflammatory diseases of the oral mucosa, the dry mouth or the infectious diseases mediated by the oral dry mouth |  |
| 10 | **US20220220079** | 2022 |  | |  | | --- | | **55**. A compound of Formula VIII   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/R-KRrBFdSVm3EnRuzSMpUOSbkAvOV_kk6XUjD_lLJUyHeHQiDXlisaWpz2xbFPEvxz2QfYDMUUOTO77w1eGzKX12IhqZIuOjW6SF6vzC7x_MLgui1THUk-UkgcbUXcxNftfYRPmBU27FFrswMOtQ7GbtyNgdIZiGGf97BoVXLYrLlR6F8d8L283IbtTX46h5) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/IFuDUV-qivZmqTX4R6I5EkewcJo1Zlvg_MX1jz9AzfgVX0WzyTVWTFV7vq1LrgiK4MWBfm99jOOXaobm7ZxrkiSbspOCzq_owMBiPef7KjpoJmUD4O3GZCkuxAFValxzvVCGw80jzit01TDaA_VSdLEPsiqzuHoVw61gWLFrJ82EtOUWc84bnKjrBxWCBLXR)  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof,  wherein RH independently represents  1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid, aspartic acid, camphoric acid, capric acid, caproic acid, cinnamic acid, cyclamic acid, dodecylsulfuric acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lauric acid, malonic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, oleic acid, oxalic acid, palmitic acid, proprionic acid, pyroglutamic acid, sebacic acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid  or   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/oPeeYIxA6RbJCn1iS0Ioi_whA5ZymDmii9t_H0mE6hHJwQAHIz4BTLWFgFBwRbgr-hoVx2_P2oRHAtWcoe_3LFX1mJJ9m5gkjEww5uOfyJWVUeX4ffV0l6K4vxkm6ljObl_66hupTDuBmx2N94eqYP5hAK67CXUnQdTATi7dCVOYnjSS8cHhz4W2HU-u4p5l) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/3iOi6-WFzZ3moAipBssCkSCnuHdF9piw4O35IgKOHSyFJpWFSS6_jdkyY8nakj5K40LL0dXwtmQYLZI5t3FG47pU-WK-yeOYDSAZjOysL3RD1dEPirItt2bGXWLW6I-_e69qXqfsRM1peK9QOHduV4bD25RHojdmRKm0ltMZzMOGd0dlCbFGOtI0kCzLFCgA)  wherein, within the proviso  R 1, R 2, R 3independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/UUrygBWV2yeOrJ4chh-t7x1c470kfVeXKQmvCBF_Z8uoAUCXbASAdfn_ZjsiXesVskvBd2MGTb91gXJa52wF_aTGPv3ZhL6ALAZQu8gODptnUosHJKQO4Co6XkqhSpXqEHQvofDbFVmnGTpQt0XiZQuCnuebxbZRIiV6hCImPky5Lqpyj7fkf2nupmx-i_Ta) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/DGenUjadoFYJNnUs0Uo32ZJKlW0kcADdKinRJidTdEqUhpJLBlN9Ufw8U-rAOS0TuwnlbeDfqo4TF-KPUMDUcxR07d-y0caDD0Fs-H7ciNeyPKGmP89iAxieTi-wmWe-vSF8yvTr-Mz3l1-op6rLCxrj00zHHkaPlo22Vs0TmHasiFBM0IPslYmg1Lhkubl7) | | **56**. A pharmaceutical composition comprising a compound of [**claim 55**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00055) and a pharmaceutically acceptable carrier. | | **57**. The pharmaceutical composition of [**claim 56**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00056), wherein said pharmaceutical compound is formulated to treat a patient in need with an effective amount of said pharmaceutical compound by administering the patient in need with an effective amount of said pharmaceutical compound by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **58**. A pharmaceutical composition of [**claim 57**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00057) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | **59**. A compound of [**claim 55**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00055), wherein the formula VIII comprises   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/41yyvC7wT3sGJMJZsPO6TBCppcBNqAzjoPbgJttSfUc9volgv2g8hfaDL42-smKab4hVbs1KEJfl4IU1TKLCHC3yqhLObGoPmAcab99TAMQIcs3LZh63otW9HZWf_5dBl0AhcuJ9qlweBpcFrShiGEuORzBSwOvGwp8UcBIF8e2kJ-86u2unQmn_hGTTv044) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US368470111/file/gJPO7HRC0XNlE6ggTsk3Cindq-FaT_YSGVm02pYSxXWBcjM6ms4J41lKEf-FTgU1TNXrtEG5cpG_C-45hRoHDzRKorAYyJ9aU32aIxJWZjVXJ0eg9o72oIKRsGFJpObin_HkJV60RrI-1KCSTtAo5iLmnuRGzlZhimavUYdL7EQSIO3a5Mkxs1eroS6AhoKB) | | **60**. A pharmaceutical composition comprising a compound of [**claim 59**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00059) and a pharmaceutically acceptable carrier. | | **61**. The pharmaceutical composition of [**claim 60**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00060), wherein said pharmaceutical compound is formulated to treat a patient in need with an effective amount of said pharmaceutical compound by administering the patient in need with an effective amount of said pharmaceutical compound by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **62**. A pharmaceutical composition of [**claim 61**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US368470111&_cid=P12-L94YFK-21720-1#CLM-00061) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases. |  |
| 11 | **US20220213043** | 2022 |  | |  | | --- | | A compound of Formula II   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/ID0DNJISdNAR-_1qkOnMuuUyvLtfetCv_a9vHy281WEzwj6cicisNcLm09e1-vzam4wG9cAw5wp3zfVYLKil3XhnxdJqxyEVlWywSje0FEppzuRVcPwCyuvdlwJmiZJ-UOgo6FCkk3QoD6DExfc0wlBrDfj7rV9JAOmxndw8-0h7BwsuQQ3Aw8VemDMFpdp-) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/Th1exGi6cyn9voa8ZlUM1HBVD44CTb5afVr_feMYp4jrABpC52toqur5qql6anjtaorrup9ST6ejFEIu5n-24ooJ7pZdfjj3vBp1znZ_8DWUvj8HYAKGA86WaJd5Ndn0fW3kbR3CQevGxptXrHDY_gwqH0f65y0k2QsbltvFj9DTbXZJNMQ1TOvwf4t82FbX)  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  RH independently represents  1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, adipic acid, ascorbic acid, aspartic acid, camphoric acid, caproic acid, caproic acid, cinnamic acid, cyclamic acid, dodecylsulfuric acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, glucuronic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lauric acid, malonic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, oleic acid, oxalic acid, palmitic acid, proprionic acid, pyroglutamic acid, sebacic acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprylic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid, arachidonic acid  or   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/ktog-AqdwFyJSRyYJEozViwM6Grg50cXaldQYJMCrZhs96SP48Eq5jI9RM1oDzBMo_Td722bqWbMOgSnz-kIRdpvYw4jElKtA7zPFxH9ErB63ZYTIz3wQa6n6WYrcCwP9cQ7R0YScwOsAUeWNZyKxLCx-GGrpbXYltMW1K_K2Jd5_GweMbaEmHhO8BmYdzNu) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/3VQ_UKVxWNLASM1aWFalg5jvr0DaX2kv5OjDqeirIX05Zq66jXKjMHBcrfULgSjx8cc_h_YlQY2lpoTZSSqG8US-g7bU-tnGxatDXau8zD-9AmEi8V-48emarBGYMaYC_fs94cWvsepmxajD6YfxvOadrcUqZ0fel4PZ9eMrvOV3OaVvjKJfXKWxQQzokTdo)  wherein, within the proviso  R 1, R 2, R 3independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/L2FmyaPzx4vAolvwOlPHCb7DKNmaETRHnXz5v4N6OFU4Ypi_4oQoacOSRugVyZiOy8cgdURWBdjo0uJ3J0ep8BeIT5QErDS29jh8HruDf9bGerZ4buy1lXhArBEQqZKm4a_j2qFy-pssylPGBkzCVQL--23WJ7bJveV3vNqEpl0pwFTP-7WEWcJulRN7aA_U) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/VmFI3TU6wNu7nmG_1XLPiL7AkEmU7cX4j8F9dnXzjl02hNE6yUBBRrcF5FKi1oFigw2CC11GjCVwH-q03SBrN9uFZPDIMBIF2KfeMdTSPART6vgWtWbIpMSzB82RmGrUqjFyDecJEG1sAFwMPyFVbckqrQ85E1U3T02PuP5oK7c-NX3xe3C-4MdFFqNrys1S) | | **3**.- **13**. (canceled) | | **14**. A pharmaceutical composition comprising a compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00002) and a pharmaceutically acceptable carrier. | | **15**.- **25**. (canceled) | | **26**. The pharmaceutical composition of [**claim 14**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00014), wherein said pharmaceutical compound is formulated to treat a patient in need an effective amount of said pharmaceutical compound by administering the patient in need with an effective amount of said pharmaceutical compound by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **27**.- **37**. (canceled) | | **38**. A pharmaceutical composition of [**claim 26**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00026) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | **39**.- **49**. (canceled) | | **50**. A compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00002), wherein formula II comprises   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/7cbqVounwmnq1Dvpba1eEW1lhkxxq5K1ZEfe1lbvUSjhNtxE-U7hmcXkBgU-By-AOEcO2Cid3gsyReRRcs-f7S34Lls9HO4Yb8CsKz-CjBJHPZkTig5Xz3M1haft7VdtoRIuo2EduGz_aT7KYTXbR0wtSHJ8yey4__9z8esGIB5QvtKgymIWy80MQG0FTw4l) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934618/file/bSFirG-dVzOjkIK_Tx6dy0c3yFVxuIEPLc7HFKX8sepLPbgJN0eJZIVpxmjhz7akHaqYBw-nEOl9JXXztd0QlozjZg7HwHzzSmzrhdIoeBcU21Nm4u__5NWAjtRx5ygKGe5VwsF9l47yzrtZRUPYzlHDwzW7cW5dJFTyusA6zUW_wlBRRFi42LYvlTdob50y) | | **51**.- **54**. (canceled) | | **55**. A pharmaceutical composition comprising a compound of [**claim 50**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00050) and a pharmaceutically acceptable carrier | | **56**. The pharmaceutical composition of [**claim 55**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00055), wherein said pharmaceutical compound is formulated to treat a patient in need with an effective amount of said pharmaceutical compound by administering the patient in need with an effective amount of said pharmaceutical compound by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | **57**. A pharmaceutical composition of [**claim 56**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934618&_cid=P12-L95RHN-89518-2#CLM-00056) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 12 | **US20220213073** | 2022 |  | |  |  | | --- | --- | |  |  | | **1**. A compound of Formula I   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/KTNnx0OqQcrSpmxeUFJugQGjVb1aswCNjHAEtbXNCgmabODese_jdum9qB5DYWiVUg0Hji_jEPm7vf5cXed9nBnfvMuFOX-haEIexknjok8ERd7TbZ6o0n8vC2z_qKsPYhyDuxlh7cJRuayw6gz0PdkY7wauA69ZDB3cmsnXBtOg5rNHOtYA2-pE9jjGjmhd) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/69xik3jXmFBSnl5Mhim7Oj0PN0vkumiDJnPeJz068Ejb8b8qP_KuMG6lxF2UgKX870NJBQ5N5wApxpaFooWFo8qOJXX9WFmnp-TyIHClSMriOWu2oPyrv44ZYCloXgAM0iaYJAPblUqoNpGrkvboqQcyL6KJyJWVT25g3wmFVE1QkXfwiQNWO8Ztp1Wg07Ef)  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein  RH represents selected from 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid and arachidonic acid;  or   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/2yzR9to6AgI8GUpx8tQuOAt13ThUHTrj70b8lDKUu3oO_rQGsbnIy6bebBm5XkxJUkcKvURQNPF8ew0HRe-jLYrB5rxYOL-dm86WK2bJ6M4_I5N4fRviPmLL0UFyJSDjCL4tNDFfAJptRGzBi9gLHUHqsA8UeKCX5_G_GhH4DAhdlaKTikeO-6vNc0oZJURv) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/gVA4l0W1lqAtWlS8UREw0ujmXwulh1tPaTE3fJVvGsvvR6cg8tukmVTnRbi4N-PSDCNmZO-_6e1Z0dal6IstBMECSxV0kI9m6YXS_WFURg7_8-eArnlPqE6XDq64KbIDnUI_JJCcXgcdkjGvPPjuJsk8nVVcsNx4afdIx76SOTRGBa5Z-57DpNWPx7nJd1nB)  wherein  each R 1, R 2and R 3independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/Crh1f2f4LiAiS1wDLKKJ-HgrusDh4KzxEfvoiDQ8mT09P90I0YgJDLIemD3ujZN5sw0M_lj68WaaapbgUc9nuAryvtPO3GN4QRr3G28_iGw4BMB7W3MgRTeohrDXJG3GsQB493H9BOTQ17R1OJBwXTC7km4OhxZsz_a8VWymGmP4wV_SLm6kkwUu8lPtP1TG) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/tUYxo-wli9lZVPEy8391ONy6RSr77GoaAtRb4t_HxNM07OOen8EiNR73YsOThvBJ1W1YJsjoHOUbd2pbleWBcOJ01TFILvcWXwtBFIhz9ayz9171kX0Hk38tzR8AHY6p0rx9w7OLx7LXHDFmO98ZRtFtsOO4gg7V4qcrl74E2uSXpvVNYX1NNY3gMobg82Uc) | | | **2**.- **5**. (canceled) | | | **6**. A composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00001) and a pharmaceutically acceptable carrier. | | | **7**.- **10**. (canceled) | | | **11**. The pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00006), wherein said pharmaceutical composition is formulated with an effective amount of compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00001) for oral administration, transmucosal administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration. | | | **12**.- **15**. | | | **16**. A pharmaceutical composition of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00011) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | | **17**.- **20**. (canceled) | | | **21**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the compound has the chemical structure is selected from the group consisting of:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/diOhQrQnajHASTIjx6XcXK2XFi-rAOUoLPzyKbrslOfMRtd1CFctjJcHNJm2had9CfAdxH60iz_N7eUBHLDbF4FxWiivgKdpWG1ywWB0ckVH9Jf3nSHIuT6S6GYJIRbUdQFfJ88FGJmJaFbKylqZtVZQ6IzjBxpAHolRHMpSa4dEPNRwzNLTnK6ufVYIEuvI) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US367934652/file/Wgyl3m1ocp2HIRTFGQe8VQ-3b5LaA6Ebi5DBnl3NUN4h5Ke6xzsSEBcOBA0DLOgp1EIp31OUHLcapkKS5mZ-_-hq14fY0T-SDkYArYdHSBnLxxFq-gQ8D6QVKj5Zc6NSXhapput1rpk98SNxF2JI_Mb_2zKYAs3q2iWWYXzmK0fWJSR6KHZ_uHouIWxZANbN) | | | **22**.- **32**. (canceled) | | | **33**. A pharmaceutical composition comprising a compound of [**claim 21**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00021) and a pharmaceutically acceptable carrier. | | | **34**. The pharmaceutical composition of [**claim 33**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00033), wherein said pharmaceutical composition is formulated with an effective amount of compound of [**claim 21**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00021) for oral administration, transmucosal administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration. | | | **35**. (canceled) | | | **36**. (canceled) | | | **37**. A pharmaceutical composition of [**claim 34**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US367934652&_cid=P12-L95RHN-89518-2#CLM-00034) formulated for the treatment of fungal infections, candidiasis and oral infectious diseases. | | | **38**.- **40**. (canceled) | | | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 13 | **US20220193054** | 2022 |  | |  | | --- | | **1**. A pharmaceutical composition comprising: Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof. | | **2**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 1:1:1 to 100:50:1. | | **3**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 4:2:1 to 50:25:1. | | **4**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein Fexofenadine or salt or hydrates or solvates thereof is present in an amount ranging from 20 mg to 500 mg. | | **5**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein Famotidine or salt or hydrates or solvates thereof is present in an amount ranging from 10 mg to 100 mg. | | **6**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein Melatonin or salt or hydrates or solvates thereof is present in an amount ranging from 1 mg to 80 mg. | | **7**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition further comprises a pharmaceutically acceptable excipient. | | **8**. The composition of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00007), wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an anti-foaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or amino acid derivatives, a bulking agent, an anti-tacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer. | | **9**. The composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00008), wherein the fatty acid or derivative thereof comprises any or a combination of: diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate. | | **10**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient. | | **11**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient. | | **12**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient. | | **13**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof and Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient. | | **14**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the portions are compressed together to obtain a tablet dosage form, optionally coated with a seal coat. | | **15**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Fexofenadine hydrochloride in an amount of 60 mg, Famotidine in an amount of 40 mg, Melatonin in an amount of 4 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient. | | **16**. The composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001), wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Fexofenadine hydrochloride in an amount of 120 mg, Famotidine in an amount of 40 mg, Melatonin in an amount of 3 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient. | | **17**. A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001). | | **18**. Use of a pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US366104995&_cid=P12-L95RHN-89518-2#CLM-00001) in preparation of a medicament for treatment of any of a dermatological disease, an inflammation associated with COVID 19, a gastrointestinal disease and a sleep disorder in a patient in need thereof. | | treatment of urticaria, atopic dermatitis, pruritus and the like acute or chronic allergic reactions and/or dermatological diseases/conditions, and sleep disorders. |  |
| 14 | **WO2022130040** | 2022 |  | 1. A pharmaceutical composition comprising: Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof.  2. The composition of claim 1, wherein the composition comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging froml: l: l to 100:50:1.  3. The composition of claim 1, wherein the composition comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof in a weight ratio ranging from 4:2: 1 to 50:25: 1.  4. The composition of claim 1 , wherein Fexofenadine or salt or hydrates or solvates thereof is present in an amount ranging from 20 mg to 500 mg.  5. The composition of claim 1, wherein Famotidine or salt or hydrates or solvates thereof is present in an amount ranging from 10 mg to 100 mg.  6. The composition of claim 1 , wherein Melatonin or salt or hydrates or solvates thereof is present in an amount ranging from 1 mg to 80 mg.  7. The composition of claim 1, wherein the composition further comprises a pharmaceutically acceptable excipient.  8. The composition of claim 7, wherein the pharmaceutically acceptable excipient is selected from any or a combination of: a diluent, an anti-oxidant, a preservative, an alkalizing agent, a buffering agent, a disintegrant, a binder, an anti-foaming agent, a solvent, a glidant, a lubricant, a flavoring agent, a sweetener, a coating agent, a rate controlling polymer or non-polymer, a zinc salt, a fatty acid or derivative thereof, an amino acid or metabolites or amino acid derivatives, a bulking agent, an anti-tacking agent, an emulsifier, a surfactant, a plasticizer and a stabilizer.  The composition of claim 8, wherein the fatty acid or derivative thereof comprises any or a combination of: diglyceryl lauryl fumarate, diglyceryl lauryl succinate, and diglyceryl capryl succinate.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  The composition of claim 1 , wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Famotidine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof, Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, wherein the intra-granular portion comprises Fexofenadine or salt or hydrates or solvates thereof and Famotidine or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient, and the extra-granular portion comprises Melatonin or salt or hydrates or solvates thereof and a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the portions are compressed together to obtain a tablet dosage form, optionally coated with a seal coat.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Fexofenadine hydrochloride in an amount of 60 mg, Famotidine in an amount of 40 mg, Melatonin in an amount of 4 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  The composition of claim 1, wherein the composition comprises an intra-granular portion and an extra-granular portion, and wherein the intra-granular portion comprises Fexofenadine hydrochloride in an amount of 120 mg, Famotidine in an amount of 40 mg, Melatonin in an amount of 3 mg, and a pharmaceutically acceptable excipient, and the extra-granular portion comprises a pharmaceutically acceptable excipient.  A method of treating oral and gastrointestinal disorders in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition of any of the preceding claims.  Use of a pharmaceutical composition of any of the preceding claims in preparation of a medicament for treatment of any of a dermatological disease, an inflammation associated with COVID 19, a gastrointestinal disease and a sleep disorder in a patient in need thereof. | treatment of urticaria, atopic dermatitis, pruritus and the like acute or chronic allergic reactions and/or dermatological diseases/conditions, and sleep disorders. |  |
| 15 | **DK3522873** | 2022 |  | 1. Forbindelse af formel I:    og farmaceutisk acceptable hydrater, solvater, enantiomerer og stereoisomerer deraf til anvendelse i behandling af xerostomi, mundtørhed og mundtørhed ved Sjögrens syndrom;  hvor,  RH uafhængigt repræsenterer omega-3 fedtsyrer, omega-6 fedtsyrer, alfaliponsyre eller R-liponsyre.  2. Farmaceutisk sammensætning omfattende en forbindelse ifølge krav 1 og en farmaceutisk acceptabel bærer.  3. Den farmaceutiske sammensætning ifølge krav 2, som er formuleret til at behandle den underliggende ætiologi med en effektiv mængde ved indgivelse til patienten, som har behov derfor, via oral indgivelse, forsinket frigivelse eller langvarig frigivelse, transmucosal, sirup, topikal, parenteral indgivelse, injektion, subdermal, oral opløsning, rektal indgivelse, bukkal indgivelse eller transdermal indgivelse. | oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 16 | **WO2022123511** | 2022 |  | A pharmaceutical composition comprising fexofenadine or a salt or a hydrate or a solvate thereof and a zinc salt, said composition being formulated as a liquid formulation meant for nasal administration.  The composition as claimed in claim 1, wherein the composition comprises fexofenadine or a salt or a hydrate or a solvate thereof and a zinc salt in a weight ratio ranging from 1: 1 to 1:20.  The composition as claimed in claim 1, wherein the composition comprises fexofenadine or a salt or a hydrate or a solvate thereof and a zinc salt in a weight ratio ranging from 1:1.5 to 1:10.  The composition as claimed in claim 1, wherein the composition further comprises an excipient.  The composition as claimed in claim 1, wherein the composition further comprises any or a combination of other active agents selected from the group comprising: a corticosteroid, a 5-HT1 agonists, an ergolines, a TCA, an anticonvulsant, an antihistamine, an anti-allergy agent, an aminothiol, an anti-inflammatory agent, immunosuppressant, nitric oxide releasing drugs, PDE inhibitor, JAK inhibitor, TCAs and a bronchodilator.  The composition as claimed in claim 4, wherein the excipient is selected from any or a combination of: a diluent, an antioxidant, a preservative, a solvent, a polyhydric alcohol, a sugar alcohol, a fatty acid or derivative thereof, an amino acid or metabolite or derivative thereof, a surfactant, a solubilizer and a stabilizer.  The composition as claimed in claim 1, wherein the composition comprises:  fexofenadine or a salt or a hydrate or a solvate thereof in an amount ranging from 0.02% w/v to 2% w/v;  a zinc salt in an amount ranging from 0.02% w/v to 5% w/v;  a polyhydric alcohol in an amount ranging from 5% w/v to 30% w/v;  a surfactant in an amount ranging from 1% w/v to 30% w/v;  a sugar alcohol in an amount ranging from 0.5% w/v to 25% w/v; and  water in an amount ranging from 35% w/v to 90% w/v.  The composition as claimed in claim 7, wherein the polyhydric alcohol is selected from polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and mixtures thereof.  The composition as claimed in claim 7, wherein the sugar alcohol is selected from sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and mixtures thereof.  The composition as claimed in claim 7, wherein the composition comprises a preservative in an amount ranging from 0.01% w/v to 5% w/v, said preservative being benzyl alcohol.  The composition as claimed in claim 7, wherein the surfactant comprises a combination of microcrystalline cellulose and sodium carboxymethyl cellulose.  A pharmaceutical composition comprising fexofenadine or a salt or a hydrate or a solvate thereof, wherein said composition is formulated as a liquid formulation meant for nasal administration, and wherein said liquid formulation turns into a gel upon nasal administration.  A pharmaceutical composition comprising fexofenadine or a salt or a hydrate or a solvate thereof and a zinc salt, said composition being formulated as a liquid formulation meant for nasal administration, wherein said composition comprises a combination of microcrystalline cellulose and sodium carboxymethyl cellulose in an amount ranging from 0.1% w/v to 10% w/v.  A pharmaceutical composition comprising fexofenadine or a salt or a hydrate or a solvate thereof and a zinc salt, said composition being formulated as a liquid formulation meant for nasal administration, wherein said composition comprises propylene glycol in an amount ranging from 0.1% w/v to 15% w/v.  The composition as claimed in claim 5, where in the other active agents is selected from beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone furoate, fluticasone propionate, mometasone, triamcinolone, prednisone, desloratadine, azelastine, cetirizine,  terfenadine, chlorphenamine, levocetirizine, montelukast, loratadine, bilastine, levalbuterol, olopatadine, brompheniramine, benralizumab, chlorpheniramine, clemastine, cromolyn, cyproheptadine, ibuprofen, diphenhydramine, hydroxyzine, promethazine, triprolidine, ketotifen, naphazoline, pheniramine, methylprednisolone, dexamethasone, pseudoephedrine, phenylephrine, albuterol, ipratropium bromide, vilanterol, salbutamol, salmeterol, formotero 1, oxymetazoline, xylometazoline, amidrine, fluticasone, glycopyrronium, tiotropium, arformoterol, theophylline, aminophylline, ipratropium, bitolterol, carbuterol, fenoterol, isoetarine, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, levosalbutamol, terbutaline, tulobuterol, bambuterol, clenbuterol, formoterol/arformoterol, salmeterol, salmefamol, abediterol, carmoterol, indacaterol, olodaterol, vilanterol, epinephrine, hexoprenaline, isoprenaline (isoproterenol), orciprenaline (metaproterenol), beclomethasone, budesonide, ciclesonide, aclidinium bromide, ipratropium bromide, oxitropium bromide, tiotropium bromide, umeclidinium bromide, acefylline, ambuphylline, aminophylline, bamifylline, choline theophyllinate, caffeine, doxofylline, enprofylline, etamiphylline, proxyphylline, theophylline, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, cysteamine HC1, azathioprine, mycophenolic acid, leflunomide, teriflunomide, ciclosporin, pimecrolimus, tacrolimus, voclosporin, lenalidomide, pomalidomide, thalidomide, apremilast, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, baricitinib, blisibimod, nilotinib, filgotinib, tofacitinib, upadacitinib, abatacept, belatacept, etanercept pegsunercept, aflibercept, alefacept, rilonacept, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate, isoamyl nitrite, almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergocryptine, dihydroergotamine, ergotamine, lisuride methylergometrine, methysergide, amitriptyline, nortriptyline, imipramine, carbamazepine, oxcarbazepine, topiramate, valproate, apremilast, arofylline, atizoram, benafentrine, catramilast, CC-1088, CDP-840, CGH-2466, cilomilast, cipamfylline, crisaborole, denbutylline, difamilast, drotaverine, etazolate, filaminast, glaucine, HT-0712, ICI-63197 indimilast, irsogladine, lavamilast, lirimilast, lotamilast, luteolin, mesembrenone, mesembrine, mesopram, oglemilast, piclamilast, pumafentrine, revamilast, Ro 20-1724, roflumilast , rolipram, ronomilast, RPL-554, RS-25344, tetomilast, tofimilast, YM-976, zardaverine, ibudilast , roflumilast, adibendan, amrinone (inamrinone), anagrelide, benafentrine, bucladesine, carbazeran, cilostamide, cilostazol, enoximone, imazodan, KMUP-1, meribendan, milrinone, olprinone, parogrelil, pimobendan,  pumafentrine, quazinone, RPL-554, siguazodan, trequinsin, vesnarinone, zardaverine, acetildenafil, aildenafil, avanafil, beminafil, benzamidenafil, dasantafil, icariin, gisadenafil, homosildenafil, lodenafil, mirodenafil, MY-5445, nitrosoprodenafil, norcarbodenafil, SCH-51866, sildenafil, sulfo aildenafil, T-0156, tadalafil, udenafil, vardenafil, abrocitinib, baricitinib, filgotinib, momelotinib, oclacitinib, peficitinib, ruxolitinib, tofacitinib, tasocitinib, CP-690550, upadacitinib, atiprimod, AZD-1480, baricitinib, chz868, cucurbitacin I (elatericin B, JSI-124) CYT387 lestaurtinib, NSC-7908, NSC-33994, pacritinib, peficitinib, ruxolitinib, SD-1008, cer co spor amide, decernotinib (VX-509), peficitinib, TCS-21311, WHI-P 15 ZM-39923, ZM-449829, other derivatives and analogs and combinations thereof.  A method of treating an allergic condition in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the composition of any of the preceding claims.  Use of the pharmaceutical composition of any of the preceding claims in preparation of a medicament for the treatment of an allergic condition in patient in need thereof.  A method for manufacturing the nasal pharmaceutical composition of claim 1 comprising the steps of:  a. preparing a premix 1, wherein the premix 1, comprises of adding ZnSO4.7H2O, xylitol, glycerol, and water, in a compounding vessel to obtain a mixture using an overhead stirrer;  b. preparing a premix 2, wherein in premix 2, comprises of propylene glycol, benzyl alcohol and polysorbate 20 or polysorbate 80 is selected and is mixed in another compounding vessel using magnetic stirrer;  c. fexofenadine HC1 is added to the premix 2 and allowed to dissolve completely; d. solution from step (c) is mixed into premix 1 from step (a) and allowed to dissolve completely to obtain the desired composition; and  e. final volume of the nasal composition from step (d) is adjusted with water. | treatment of allergic conditions/diseases. |  |
| 17 | **US20220184052** | 2022 |  | 1. A pharmaceutical composition comprising fexofenadine, or a salt or a hydrate or a solvate thereof, and a zinc salt, wherein said composition is formulated as a liquid formulation for nasal administration.  2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises fexofenadine, or a salt or a hydrate or a solvate thereof, and a zinc salt in a weight ratio ranging from 1:1 to 1:20.  3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises fexofenadine, or a salt or a hydrate or a solvate thereof, and a zinc salt in a weight ratio ranging from 1:1.5 to 1:10.  4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises at least one excipient.  5. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition further comprises at least one other active agent selected from the group consisting of a corticosteroid, a 5-HT1 agonists, an ergolines, a TCA, an anticonvulsant, an antihistamine, an anti-allergy agent, an aminothiol, an anti-inflammatory agent, immunosuppressant, a nitric oxide releasing drug, a PDE inhibitor, a JAK inhibitor, a TCA, a bronchodilator and any combination thereof.  6. The pharmaceutical composition of claim 4, wherein the at least one excipient is selected from the group consisting off a diluent, an antioxidant, a preservative, a solvent, a polyhydric alcohol, a sugar alcohol, a fatty acid or derivative thereof, an amino acid or metabolite or derivative thereof, a surfactant, a solubilizer, a stabilizer and any combination thereof.  7. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises  fexofenadine or a salt or a hydrate or a solvate thereof in an amount ranging from 0.02% w/v to 2% w/v;  a zinc salt in an amount ranging from 0.02% w/v to 5% w/v;  a polyhydric alcohol in an amount ranging from 5% w/v to 30% w/v;  a surfactant in an amount ranging from 1% w/v to 30% w/v;  a sugar alcohol in an amount ranging from 0.5% w/v to 25% w/v; and  water in an amount ranging from 35% w/v to 90% w/v.  8. The pharmaceutical composition of claim 7, wherein the polyhydric alcohol is selected from the group consisting of polyhydric alkanes, polyhydric alkane esters, polyalkene glycols, and any mixtures thereof.  9. The pharmaceutical composition of claim 7, wherein the sugar alcohol is selected from the group consisting of sorbitol, xylitol, mannitol, maltitol, inositol, allitol, altriol, dulcitol, galactitol, glucitol, hexitol, iditol, pentitol, ribitol, erythritol, and any mixtures thereof.  10. The pharmaceutical composition of claim 7, wherein the pharmaceutical composition comprises a preservative in an amount ranging from 0.01% w/v to 5% w/v, and wherein said preservative is benzyl alcohol.  11. The pharmaceutical composition of claim 7, wherein the surfactant comprises a combination of microcrystalline cellulose and sodium carboxymethyl cellulose.  12. A pharmaceutical composition of claim 1, wherein said liquid formulation turns into a gel upon nasal administration.  13. A pharmaceutical composition of claim 1, wherein said composition comprises a combination of microcrystalline cellulose and sodium carboxymethyl cellulose in an amount ranging from 0.1% w/v to 10% w/v.  14. A pharmaceutical composition of claim 1, wherein said composition comprises propylene glycol in an amount ranging from 0.1% w/v to 15% w/v.  15. The pharmaceutical composition of claim 5, wherein the other active agents is selected from a group consisting of beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone furoate, fluticasone propionate, mometasone, triamcinolone, prednisone, desloratadine, azelastine, cetirizine, terfenadine, chlorphenamine, levocetirizine, montelukast, loratadine, bilastine, levalbuterol, olopatadine, brompheniramine, benralizumab, chlorpheniramine, clemastine, cromolyn, cyproheptadine, ibuprofen, diphenhydramine, hydroxyzine, promethazine, triprolidine, ketotifen, naphazoline, pheniramine, methylprednisolone, dexamethasone, pseudoephedrine, phenylephrine, albuterol, ipratropium bromide, vilanterol, salbutamol, salmeterol, formoterol, oxymetazoline, xylometazoline, amidrine, fluticasone, glycopyrronium, tiotropium, arformoterol, theophylline, aminophylline, ipratropium, bitolterol, carbuterol, fenoterol, isoetarine, pirbuterol, procaterol, reproterol, rimiterol, salbutamol, levosalbutamol, terbutaline, tulobuterol, bambuterol, clenbuterol, formoterol/arformoterol, salmeterol, salmefamol, abediterol, carmoterol, indacaterol, olodaterol, vilanterol, epinephrine, hexoprenaline, isoprenaline (isoproterenol), orciprenaline (metaproterenol), beclomethasone, budesonide, ciclesonide, aclidinium bromide, ipratropium bromide, oxitropium bromide, tiotropium bromide, umeclidinium bromide, acefylline, ambuphylline, aminophylline, bamifylline, choline theophyllinate, caffeine, doxofylline, enprofylline, etamiphylline, proxyphylline, theophylline, pranlukast, zafirlukast, zileuton, ramatroban, seratrodast, cysteamine HCl, azathioprine, mycophenolic acid, leflunomide, teriflunomide, ciclosporin, pimecrolimus, tacrolimus, voclosporin, lenalidomide, pomalidomide, thalidomide, apremilast, sirolimus, everolimus, ridaforolimus, temsirolimus, umirolimus, zotarolimus, baricitinib, blisibimod, nilotinib, filgotinib, tofacitinib, upadacitinib, abatacept, belatacept, etanercept pegsunercept, aflibercept, alefacept, rilonacept, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate, isoamyl nitrite, almotriptan, avitriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, dihydroergocryptine, dihydroergotamine, ergotamine, lisuride methylergometrine, methysergide, amitriptyline, nortriptyline, imipramine, carbamazepine, oxcarbazepine, topiramate, valproate, apremilast, arofylline, atizoram, benafentrine, catramilast, CC-1088, CDP-840, CGH-2466, cilomilast, cipamfylline, crisaborole, denbutylline, difamilast, drotaverine, etazolate, filaminast, glaucine, HT-0712, ICI-63197 indimilast, irsogladine, lavamilast, lirimilast, lotamilast, luteolin, mesembrenone, mesembrine, mesopram, oglemilast, piclamilast, pumafentrine, revamilast, Ro 20-1724, roflumilast, rolipram, ronomilast, RPL-554, RS-25344, tetomilast, tofimilast, YM-976, zardaverine, ibudilast, roflumilast, adibendan, amrinone (inamrinone), anagrelide, benafentrine, bucladesine, carbazeran, cilostamide, cilostazol, enoximone, imazodan, KMUP-1, meribendan, milrinone, olprinone, parogrelil, pimobendan, pumafentrine, quazinone, RPL-554, siguazodan, trequinsin, vesnarinone, zardaverine, acetildenafil, aildenafil, avanafil, beminafil, benzamidenafil, dasantafil, icariin, gisadenafil, homosildenafil, lodenafil, mirodenafil, MY-5445, nitrosoprodenafil, norcarbodenafil, SCH-51866, sildenafil, sulfoaildenafil, T-0156, tadalafil, udenafil, vardenafil, abrocitinib, baricitinib, filgotinib, momelotinib, oclacitinib, peficitinib, ruxolitinib, tofacitinib, tasocitinib, CP-690550, upadacitinib, atiprimod, AZD-1480, baricitinib, chz868, cucurbitacin I (elatericin B, JSI-124) CYT387 lestaurtinib, NSC-7908, NSC-33994, pacritinib, peficitinib, ruxolitinib, SD-1008, cercosporamide, decernotinib (VX-509), peficitinib, TCS-21311, WHI-P 15 ZM-39923, ZM-449829, other derivatives thereof, analogs thereof, and any combinations thereof.  16. A method of treating an allergic condition in a patient in need thereof comprising administering to a subject a therapeutically effective amount of the pharmaceutical composition of claim 1.  17. Use of the pharmaceutical composition of claim 1 in preparation of a medicament for the treatment of an allergic condition in patient in need thereof.  18. A method for manufacturing the pharmaceutical composition of claim 1 comprising the steps of:  a. preparing a premix 1, wherein the premix 1, comprises of adding ZnSO4.7H2O, xylitol, glycerol, and water, in a compounding vessel to obtain a mixture using an overhead stirrer or equivalent;  b. preparing a premix 2, wherein the premix 2, comprises of propylene glycol, benzyl alcohol and polysorbate 20 or polysorbate 80 is selected and is mixed in another compounding vessel using magnetic stirrer or equivalent;  c. fexofenadine HCl is added to the premix 2 and allowed to dissolve completely;  d. solution from step (c) is mixed into premix 1 from step (a) and allowed to dissolve completely; and  e. final volume of the nasal composition from step (d) is adjusted with water. | treatment of allergic conditions/diseases. |  |
| 18 | **WO2022107084** | 2022 |  | 1. A pharmaceutical composition comprising a local anesthetic or a salt or a derivative or a mixture thereof, formulated for local administration for use in the treatment of pain.  2. The pharmaceutical composition as claimed in claim 1 comprises  (a) 0.1% - 70% (w/w) local anesthetic.  (b) 30% - 99.9% (w/w) pharmaceutically acceptable excipients.  3. The pharmaceutical composition as claimed in claim 1 wherein, the local anesthetic is selected from bupivacaine glyceryl dilauryl fumarate, bupivacaine glyceryl dilauryl succinate, bupivacaine glyceryl dicapryl succinate or bupivacaine glyceryl dicapryl fumarate.  4. The pharmaceutical composition as claimed in claim 2 wherein, the composition is formulated into oral lozenge or oral chewable tablet or oral dispersible tablet or mucoadhesive tablet or buccal tablet for oral administration.  5. The pharmaceutical composition as claimed in claim 2 wherein, the composition is formulated into a topical spray, preferably into a polymeric film forming spray.  6. The pharmaceutical composition as claimed in claim 4 wherein, the composition is formulated into a sustained release formulation, extended release, modified release or an immediate release formulation.  7. The pharmaceutical composition as claimed in claim 2, wherein, the local anesthetic is present in an amount of 5 mg to 100 mg, or 5 mg to 75 mg, preferably 5 mg, 10 mg, 25 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 71 mg, 72 mg, 73 mg, 74 mg or 75 mg per unit dosage form.  8. The pharmaceutical composition as claimed in claim 6 is formulated to provide local anesthetic effect for at least 20 minutes, at least 40 minutes, at least 60 minutes, at least 80 minutes, at least 100 minutes or at least up to about 2 hours, at least up to 4 hours, at least up to 8 hours, or at least up to 10 hours.  9. The pharmaceutical composition as claimed in claim 2, wherein, the pharmaceutical acceptable excipient is selected from a binder, filler, lubricant, polymers, solubilizing  agent, surfactant, co- surfactant, solvent, co-solvent, preservatives, antioxidants, sweeting agent, flavoring agent, disintegrants, super disintegrants, taste masking agent, polymer which enhances permeation, bioavailability and retention time of the drug or a combination thereof.  The pharmaceutical composition as claimed in claim 4, wherein, the lozenge formulation comprises 5mg to 100 mg of local anesthetic and pharmaceutically acceptable excipient selected from mannitol, povidone, croscarmellose sodium, citric acid monohydrate, saccharin sodium dihydrate, colloidal silicon dioxide, peppermint flavor, magnesium stearate and dehydrated alcohol.  The pharmaceutical composition as claimed in claim 10, wherein, the lozenge formulation comprises 73.08 mg of bupivacaine glyceryl dilauryl fumarate and pharmaceutically acceptable excipient selected from mannitol, povidone, croscarmellose sodium, citric acid monohydrate, saccharin sodium dihydrate, colloidal silicon dioxide, peppermint flavor, magnesium stearate and dehydrated alcohol.  The pharmaceutical composition as claimed in claim 5, wherein, the spray formulation comprises 5-100 mg/ml of local anesthetic and pharmaceutically acceptable excipient selected from film forming polymer, preservative, sweeting agent, propelling agent and dispensing agent.  The pharmaceutical composition as claimed in claim 12, wherein, the spray formulation comprises 73 mg/ml of bupivacaine glyceryl dilauryl fumarate, caprylocaproyl polyoxylglycerides 8, sodium hyaluronate, PVP K30, sodium benzoate, xylitol, and purified water.  The pharmaceutical composition as claimed in claim 10, wherein, the bupivacaine glyceryl dilauryl fumarate is formulated as a sustained release formulation.  The pharmaceutical composition as claimed in claim 12, is formulated packed in a sprayable device to deliver uniform dose of bupivacaine glyceryl dilauryl fumarate. The pharmaceutical composition as claimed in any of the preceding claims is used in the treatment of pain.  The pharmaceutical composition as claimed in claim 16, wherein, the pain is selected from the group consisting of chronic or acute pain, nociceptive pain, general pain, neuropathic pain, inflammation mediated pain, sports pain, dental pain, wound pain, burn pain, bone pain, cancer pain, chemotherapy induced neuropathy such as stomatitis and mucositis, musculoskeletal pain, ulcers, cankers surgical pain, viral rashes, HIV rashes, post-herpetic neuralgia, and sciatica pain.  A method of treating pain comprises administering the pharmaceutical composition as claimed in any one of the preceding claims by local administration of the composition. The method as claimed in claim 18, wherein, the local administration is oral administration, spray, parenteral, depot or topical administration. | treatment and management of chronic pain, nociceptive pain, neuropathic pain, or central sensation or generalized pain or a mixed type of pain. |  |
| 19 | **US20220162171** | 2022 |  | |  | | --- | | **1**. A compound of Formula I:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/tmTdm3PEGk3nuSMxkQznvKPoErqf30f7qyOzfKIfhIrmBRLMFLBzF693dU7hqLkvjMZ21bNBxcv_4L9hSvykFzzuK-T92Scsjr8pH1IUUePnUDwI0XZHjr5D9sSzmL0o5b6AR-_i7_vjDZxdaKeFhiQMQ4WEH5Isd-QF6ctuYT1TVvHqlHimNpZBL2Yw34jF) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/glA8YpQ_Mtw32pjTYyQbNDmSx3jWbWNdXwDYl2W7hvTnalsU5WUiCc3knHoyqxf3D-q3tHfdIX5Z1Nc0pIFSieKam8Jj9y6w5zTIQm6vbH17rsc_TVRB55JAvHF3-WJx4Dw0Wo79nNgt4VZ_OUnUBtuTu7ercs0oRtX8OB52v9PJcDKW009TLNEMMiKolHzO)  and pharmaceutically acceptable salts, hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  wherein  R 1, R 3, and R 5each independently represents NULL,   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/KIFiIw8Q3i-KAY7D24JeNuPD1Hseny1ZhWemZPJ36gFS6rYR5Z8eRED4NdLHRAaTdpjuCVnCw7_qjXncl9UoHSMOJ3vkMLJA8Ijmu1-BFoB7gxEG7GfpDuNMVdXnkNb6JJzttGLtDZbQrTjW-iqPvXAxgXqxS5bAB5PwgZSXfQD2uxC4QP1C1lgM1GmBj-Jj) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/QySOaUKSpa4QDt2I5iawLZ-rtAQ-S9cQBpRAwt7syj6XKSzqHhZr36j4cIsbE10ulCgve5P3WbZHOuFyswab2H08XSdpq7EG3gmO3cgP-cyeqJSoHkbkdGE7gbcE2v0j7M-4Fg0QRvYU_11wa9qyGBc38XTikyYFPIqPp4q8GOFRCTNQLiOVp2wfvfivDEdI)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/9LhY3iNFzXBLbfPgaLrBsjh2bmDJXrHCF1XpvfqYe8dl5bwpLWTu1rnR1YGE-w3vKAB6Jxm5tDEMslZF8QVFivkU2RlxpQ9jh_liKdRhGtwprR_pDXbOy1YlpeC5HEevqSVuw5kFQMify-f3BjlRS0DInruXuHxjGhr7H11kfv9sFYaezyGsRIBuE76rs5PU) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/l5WtoAtZc4ib2clD4NfyrjAggTsP0Lptx1JzeWUhlzGUSyajjJW5ir5OT5iKhxID30IPEviCzCl9iEDNZ_nLAIKJkp9lkREw3iUAYOwGkCFOgCx6woxyiaLH4-ReuJ-8mTC_8XXqd7DnyKuDla7fKIu6NPM_6gr0sBC6_s4vgO7vKHknkBt6X4XkVDXZetdx)  R 2, R 4, and R 6each independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/zH70GEgiZl4nHcTEy1pGuh9tjcOxZHpyqqfbVvS9YXfqRctCVekV1iExiK3vhYVJCBz-2NRhMRG4waKv4ihoQCpkkV_fxr6G_WSC_5mR9tN7qXf0dmPFt9mIpW4CwOFMzf-DzMk9rT_7wgvm5iq-Rs-2Rvu1Z5C0XBGTFEbOb6LKWHemWzGiSfSJ4J_tFYa4) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/uJ1GMohf-Lg5BswUobgMX1oySiPX1Cv-LYEnqGhtObf5HV9vXZsCwC1Us8tlADyp77HcQuzJv33Q4KdxMw4I57IY-juzW5RVJ-0NPK1QtZkLf6KYQmmXrW26jxPZX65cKXgNFDcpfEeRlkRQBcxdSLqh7dUnxoTmm0MDmxcpFCXRX9askf9guUDJ_Mzn7Jqa)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/p_ijT3dSIxbdm1Od4DgLm5xr1QL-IzUt_91h1JR-GiLFOhuJxZHZCQv77w1wvVfEEsEmxRR1vZPza5E7JdpEn5WQYW3DO2nwxOIQ4rcfXMBoLRW9tMd23GRZ8u2lYjWkxgbauqZ9j68PpD75vmVLnMWhDxfkvoQylXdtdj9dcUw6O-ZUaYn3wbyDzDPfwYEV) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/5TNFq6hlspTmQJq5DZDb5hgkmPJpEdwCErjOid7KQ4QDZCixO8q5fOOddoTNKcumvNT2NPlWxC6KNllVfYhJo7hZLkUPBgEsktdrOYi_2y6RRao4-oIzFgDtU3ce6Cdam24xqcMTgt-hAMkTnhD7z787X9MBdiTpLCxos2M2fKxPdQ8LYF6-oKNaHyAoO96V)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/Xd3b_Mv4-rttDWCBZnOUt8CRwmMSC-PwHLleQ7rUXwG1ASudOFyzbOoqN94PQvt6xSeA6B4ixmq0lbpCBrIBoylPH_OmsCYe9Z_bAZbGIKCNh7Yl1Geu2GFAiKhN7hZtYzFyOycGtaprd4Lz9jUk0KgCqKMPMjJ_mte6M-5o1Ijt2AsWb6jxmMqMk_wTq9K_) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/0pmAFYhnLzBeQjOmIUB6h61kWIkeEQsoQ43UBZcOw-DqYLjpv5fVEOeUKpPgJqkDwwlNsATJxwO8hBVKMt2ivZQyMDn5qbBTenAqCjXlICuQfErhuVGIpeIedaxPa05UlCZNF3KnSTmphxoa-gywcZjp1OciimSXCx4JNSzclCTBYWDHsgejOjj-5qFn_MBK)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/wtfQs8ewDNJnSMYjrLERKQ-X-j-g7EFwuWEwhQzAdZEZ9zzYukoL6EC81IQuFxyMEG2JApxuoSB-Kusgb6w3XaA9wRAVyJeiS59zetiO9ZehF09zo_Rcjb01MHh6vGRE9iMSSZcJKyzNZ6-54A79Zln0r-fof-uWuHKoICJVTwzAB1vDL8aFRZSgFOwvIdf9) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/E7jQt3fYfCrEUDA04wjb1iZmn-zYEW3cbm4qNLLFji9uji91nAWuE-AC1DcJgl2PzfGomOYgieNuaSVaBRN_C-NS8BT6zrT9mZ8o4LHiO2iPA0EkZaUoHTbZ4O-dMSXmE3X1FJwDeJaCIeMXEieLq43D6skfVlDIw3zbonM_Of2SS_2Ob3D2em00uf7ZjvU-)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/nQJjmUcuGMgsRsG5CErj99P7W6gFBCiAvqqwJ2NKGt3tFj6YFhJT9-rtlrjVqhFuAor5uKfbc8hyzw2H1gNT3LF7hX-vxb7YVIy5YMALgDFhLCTnxO0EBNE0rP-LcXwa-DtuUPI-a273MlXTN09D6bNeZsUEdxjB2k1YZQn563mMBlxHv_QlLO2mWOsbRfWK) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/tMEbqdkJH_S9OWVVtxBL6UMlF-uGP446Gq8zQkxWYKicXv23TPgf1_hmlohbNGgAIuCpstO5v5AyFX2Fh4i6YE79vTYARtwEy4eQzIzESdLDSf6l031FmoH7PL6N1HnjZrVDexKa5rH__bi2Cdz0sXoGeeglAqIZ8mwgK0X7pxrA4Mk-Z3zQWykAnK8D6eFW)  n is independently 1, 2, 3, 4 or 5;  a is independently 2, 3 or 7;  each b is independently 3, 5 or 6;  e is independently 1, 2 or 6;  c and d are each independently H, D, —OH, —OD, C 1-C 6-alkyl, —NH 2or —COCH 3. | | **2**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00001) and a pharmaceutically acceptable carrier. | | **3**. The pharmaceutical composition of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00002), wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. | | **4**. The pharmaceutical composition of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00003) formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation. | | **5**. A method of treating at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease comprising:  administering the compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00001) to patient suffering from at least one of a gastrointestinal polyps, intestinal polyps and inflammatory disease, wherein said compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00001) is selected from the group consisting of   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/2Eeil5Zl6lDRb9g8qJF3Z0D42K08N-y3h2Y56h0x98DlbzjQ2DxdO16nu5-K4zTzdJppudw0YM8WhskPh7JRE0y43ziJwERHeHIyQ4NWYGI0sT--69IbdNySPoCSP1uVrEsubnrHJZp_q2xEDqMGlPL9NAy4OKmst6oke0FEisDR6BGXQ_ESqbQJVpgUzNxG) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064297/file/lR3mCzNVzMkq-hQJPs9sZRrxGW_JrP9prNWe5EMYuzX1_fr2VbzVOsHYUWgJgRLYWITfsb117J6XbmlykvLvuLm66HiHT29KFMdGS_xngOV0dl7_0VGGtLXp1yYGwd3CId2eAgPgXGZpu61wzVgRhCUCWaPhmSd67O3yCp96wYL6ryBxDAWGi8-b0a9BjMdG) | | **6**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00001) selected from the group consisting of: | | **7**. A pharmaceutical composition comprising a compound of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00006), and a pharmaceutically acceptable carrier. | | **8**. The pharmaceutical composition of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00007), wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. | | **9**. The pharmaceutical composition of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064297&_cid=P12-L95RHN-89518-2#CLM-00008) formulated for the treatment of gastrointestinal polyps, intestinal polyps and inflammation. | | may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 20 | **US20220162156** | 2022 |  | |  |  | | --- | --- | |  |  | | **1**. (canceled) | | | **2**. A compound of Formula II:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/ng3uMlru32Rtr9-tkG3sCQ-XGZqJ5kJkP7i3eBQAnYUbTn4_rELCjXOrgAHKLVJcoLC3jirz_N7zOZEKmXSlknMh72Pj0gHsgSHUY4TwgAHA-WOiUf_DomsAl8Xr5JJvMLcU5IK5iIErfU2uVKVkQWHo5RFufv09Au-5XWHM_7vpt_bhHEYofujcDmnsz9ZW) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/t_A_lUs6ziYdTzm6VSe4oW68CPOwQGMgHruH0_I1f4npKyPYb9L1gAQKnmt2ihuBlqJ0d78SiAukV57RHwZdoPzfdpXIRxYJcGyveqtmx7YUiVezqXglqqPpwULQGl2Z-3GmqVc5eDEn2TROZs2ivJbEJzKE-4CQ1KIIlmd5OqGVhsfjUzHDIImOXxJmUYgn)  or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, or stereoisomers thereof, wherein  R 1, R 2each independently represents NULL,   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/oz0yRqCMCjQogrwbNqZb4Fs09sT4FpD6E08hOy_lLFTFAzawR1PYtvzGyQRn5gw-T207kSxVKxt4qm0NctlmC9S1Cgvd2hB_ruRsgu9HJpARqZe5kMUEL6jQ4L-p1JFIZhhfRuZJvUqNO14g5o_PTitC17gHsLzRePq3Q_k_JuvEm63GMS5P1iwMinFnQhqA) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/8OLW7iX4UVoSw0ArJa2K-J2v5vsq94OsAncE5jVfyTKDkSTSrAKpulBuVvVzzffsplmjhWJBcamIyfUvT8Yb0un1VuOFsHreDKwUEwSFnQYZSgHi9jRYt7u8f1l0Vd1tUV2wUTPH8VI2w9etgPIcuAJH0VpK3u24qmuJihbuFVG6_sbvJqqml0FMbsfGGVIr)  R 2, R 4, R 6each independently represent D, OD,   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/CY_T39vDvPY8TUpRih_jFn6FAYVsM5y2hi0Lzxk33_Rmxsimw2WT3n8s0UE0P9l5hVZlDN441oSQ43HH6CN4LCp8Hdbt6IsD725BVs9bHLEDwyJ6yzzse1QrG6NZc6J4--rZ-VbpTaPnl_XHoMops2SbSnwC_-ktHIKG_ejd8h8Zke6yuoiRDKX-dABMkTRy) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/wAgzwbB5ewwoqmHtqlUM125opKg2LcTJNJuhUawazdp_pt1sgWoBXxra0Up6eDmNiYLgcq_2jMMMsO891Gqsn9p36sLLPTODGwP2Yve1cxS94EhdiL3srL0PCN9exOafaFLObJt8uYy6tbqjB6UgqaPHXbhXLoKMt9rrzz7iknmIc73-TwT2LPpcCdMxh1ix)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/I_XS7RnFAwxCl9xzfYkGr7TaUWJ7GisjX5kvVUQ03GVx-xrQlg8szcLDuYn8UB1Qn2Dso0A9_Cj_VM-JNkURCgtfVVck1QMxA9UjORmQZpiD3d5S32RmyhbTzYBaJh0MfSLl2Jwt1owXSigftNkt-jau1C_MeCq4T0psfI3R3AZeh9b11Rk27c-TgYidjYsf) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/36v6pHqUR1OkPu4FdD51Py9l1zpKJxP5E5uCYxG4Wb79UDnE-0LOnIa2bIn8-Vtw6t7FUG0b0ZPwOi99DLO-RPGuvETNcuLmcLHD9CCqL-P1D4uHP7rFoEv_fIK4TJT5ShcO8TJtzoD-f0xGmZd3iqOn6o0LGxfN0afFx4Yeu_M4mOXay1DKFijn-NSXdbhp)  [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/OkMIj0ziYCW4Y2iJvcRp3LyoegTfhJu4EgaGQSsFGkT6KJWBMYTz_dYSqLQmri3kMSYag8P1ampuTMcZDXPJ6Rel9IyK6vdWvRTmBj5bJrGmZA9V4Zgeai1kY4K-VUPO1T6B_m4nDqQoiptgBxUZdNTYYErNbjpTCJTYRFR932lfN_oWnKz0NRSVDwbksJ51) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/M0oFx9Lqip5f7G1Nv8RalcIC7LlDCeAG2SgWcO5FgMuQ-gMoXK_rRQvzpKCOjuvSNQco-yOItX6fmHEil_WwMkqZY6JU9WlfmDZAMsP7Kl6fA_CqzRYd83f47VvPM5kyPxVCFSO9G1bosq4DLYMefVc4xwJXEayI2HrtMXy6_mMvn_G5d7-247bSJN2PpQRr)  n is independently 1, 2, 3, 4 or 5;  a is independently 2, 3 or 7;  each b is independently 3, 5 or 6;  e is independently 1, 2 or 6;  c and d are each independently H, D, —OH, —OD, C 1-C 6-alkyl, —NH 2or —COCH 3;  within the proviso that there is   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/T2gOTk3S0K6g22f3HoOAFG7sCF--7Bagw5-NGhv5nvGhqZOrinr5Eh3VkTRRDiaCBYYnOzV32al25mzg74MPuqEQhyuvFmkU_mS8fU8t9W5BKSkecBKQhRZ5cxRsRS4wGBPkXeReod4hbgP-WjSYdYzjKIS9Kcbi5pFv_dDPUQizsbuMuWUYAI0sHZRpH7CT) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/3EG67BKESk0KuP_7IN0SCmUGZr55amJDhmCytxnuIOGcu1LOKL9SHVrukp6FQrUrf6S2kOEGrd2BULeqXeIO7bSgTFJhRMkaLIvLjZwvcix0wgkGaSVjNJfFbDbzu3jdEMLMEoZ7D1VhYH5Z1GzABg_FG90aKB5OH9Z-080ae6XuPVpCX5v6Utb8djhJ55ro)  Each i independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/-fixoXczbt-seXMAuyZ30k7nHL6yS84fkbcOwKxdn9jAGJ7-l0_dDpzq8iiOK5JFV0rOSVOT2Oxa-0-Ot51RdJTpI4JVS1qQ8hkMl67DJk1FWLda8_qFcmBBxj_4jKo3F0zPDRU8bAfESGrEwgU71dK3kfxU44Vdl5CfTgP8fLBwpXeulIsEc5pvOlzD-ouG) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/JfZh-sddVBVCpCtxcWq_B9zs5YGkIVJ0Uz-qEQ-XkEKgSIuR0dHkUPC949UNrfyl5w6DmHhMjiy03F-X2iLkf62BLC5c0pTDPLt_fspJPuz9b5_2vkE9LQvaai9ep-gcW33OW0GTnx7JPXsHLoM2U5OjosQyTaPhTdwXVjPshuYykt2NIj68RP79AFXqwsdx) | | | **3**. (canceled) | | | **4**. A pharmaceutical composition comprising a compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00002) and a pharmaceutically acceptable carrier. | | | **5**. (canceled) | | | **6**. The pharmaceutical composition of [**claim 4**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00004), wherein said pharmaceutical composition is formulated to treat a subject by administering said pharmaceutical composition to the subject by oral administration, delayed release or sustained release, transmucosal, administration, syrup, topical administration, parenteral administration, injection, subdermal, administration, oral solution, rectal administration, buccal administration or transdermal administration. | | | **7**. (canceled) | | | **8**. The pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00006), wherein said composition is formulated for the treatment of inflammatory bowel disease, crohn's disease, irritable bowel syndrome, coeliac disease, fructose malabsorption, mild infections, parasitic infections like giardiasis, bile acid malabsorption, functional chronic constipation, small intestinal bacterial overgrowth, and chronic functional abdominal pain. | | | **9**. (canceled) | | | **10**. (canceled) | | | **11**. A compound of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00002), wherein the compound is:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/8XT-rVP-aIMMnZhFukdKAeCuR8j_syKOh4_6g4WGW3j6heoxbHXWW-MJ8BUG63lfNG1YOs1Svl4tfUCUINNedKx3wMteyUnEmnOtXqgfHuPU7izPhOkY6q9ktx199FGTrAeoYwcIt1jw9cICdf2M0ckHr7V4q7S0UIWhWL5PZUkZF3MT64eZVGSzT1AWSgTR) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/vAjtUv0YmvpUB_4Lr2Fzv_zvicD-0ejuynbcqdXLvUhARgGJh4QlBHPzKaXx26wIBh0U3kNnnmBGpuagx3DM9BcQ5COHuaHpn7-hf8sbLby6w2BaQK1cCBHCmBP7bdDwQXgeSmxjpw5l72iEq-OzsUJ0wZ1ATJ8w9kdoRO_7ksBsa8lhalXSrxBKAvg13LgZ) | | | **12**. A pharmaceutical composition comprising a compound of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00011) and a pharmaceutically acceptable carrier. | | | **13**. The pharmaceutical composition of [**claim 12**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00012), wherein said pharmaceutical composition is formulated to treat a subject by administering said pharmaceutical composition to the subject by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | | **14**. The pharmaceutical composition of [**claim 13**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00013), wherein said composition is formulated for the treatment of inflammatory bowel disease, crohn's disease, irritable bowel syndrome, coeliac disease, fructose malabsorption, mild infections, parasitic infections like giardiasis, bile acid malabsorption, functional chronic constipation, small intestinal bacterial overgrowth, and chronic functional abdominal pain. | | | **15**. A method of treating at least one of an intestinal, an immune mediated disease and an inflammatory disease comprising: administering the compound of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US362064280&_cid=P12-L95RHN-89518-2#CLM-00011) to patient suffering from at least one of an intestinal, an immune mediated disease and an inflammatory disease. | | | **16**. A method of treating at least one of an intestinal disease, an immune mediated disease and an inflammatory disease by administering a compound to patient suffering from at least one of an intestinal disease, an immune mediated disease and an inflammatory disease, wherein the compound is independently selected from the group consisting of:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/4ESRTIPZnqrf82VbdIYqcOeV5TgwGT_v_fup-2VE9ZqK1ZEcGeb31--iH5CY9Rl9xglhK83SoxCtN8C_18YE9zwyxXMKDrO1-VnE2_m9jOxhgGSdYLj0sFGqD3aBPRdu_RGUl-Z2cOYOvzQmiWau1W1HcCH1a7FDKWUpN4E6TpueP1o4nauHYW9Z_bpp_Z_9) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US362064280/file/uHZ8250VJEDEWgu4WACjn-eQpOa2fIo47B5z3096Oe3z6pLkC1_Rgison0yevfRljGkdeIbFtac-9gTtgTqAb5fY7KJTAz80QZZ-mWXtI4R9LUkxqInBwHjsyzQ7pmaDVy7uZGscVJb38rVCHPPTHoKwbZmE7W5C1cJILxRTfAipqSTwQAqSsPzq_X7F648v) | | | formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. |  |
| 21 | **EP3989935** | 2022 |  |  | treating disorder affecting the anus and rectum. |  |
| 22 | **US20220105052** | 2022 |  | |  |  | | --- | --- | |  |  | | **1**- **6**. (canceled) | | | **7**. A compound of Formula VII:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/gqBbnBb9s1PE0mkg1czWe2HGt2h3SEPqZeEsvhAxesOkPdzl1NZulq9_uNPyozFcPZHE6xwI80p-rW0PS_uDq07yApdEvaE52Ip0ESD_5ZR7YrbG5akF1hxYsDKFkPkMG7iY9geaOj6CuLQB0n-DNoArpAtG5vv5s33zpW8JwkLrWHlYelk7fkioJGA9iDKi) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/IovldA8ak90Gh3eB0yUOALBuVfgdrSv4vrZ7gbKB9wZvni2wxskKx2zOPbrnDrW691w4aWT51EFzzBpEe2rsjV0_l3McHap0hufSC4qa9cTU7GJ2M-F0ciSsWUqLeGY1x2REnH5Lhus8jqEKdAR95QMtEINnFNVu_dJzErRrmGXWkE8fRKaDSyKKwc4uKt4W)  and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof; wherein;  RH independently represents caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine, furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone, menaquinones, menadione, menadiol, thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/guMSXbhYKvVeZrfGhC9su71hirw6xfklLw_GLD0YPYgNwaWRe7NPTnVF7m9dPUgDiwbNtPq6CnWUf4PF_Jvz3iyZFH3o1t-Y6hOybJ7ROMF6EYmA25XLV_hQaXPNIMCyPEKy82fgP2M-tCUf_aYO_seav2mNoO5cenpRqfNez8u4JsRFjbhK-0Ewu-emuO6S) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/7JZl8UaEkb4_x0S3mf23iHTs_-pS4tEV98m1I2nCmVhGN1bWkqRU8oiJYKDz4CLTyjKeusYSlUuHYdNXacraXjvHZdW2jS74CqSu0wkfhK5TWSLAMLIkFgyGz6IaAU2obVYKy7dIgNJQO_x-WACVLzJkwVeePeeKt_2L81tuxQHzvFM3Qd3xk2tzGDE14FuG)  wherein, within the proviso R 1, R 2and R 3independently represent   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/0uQCqB2FgT01H5wxbVACvDXRcWNsQ08CQJQe4aEQiJ1a6bsTRbMtiCksYrg00jJlS3xisy6H8ppKU0oJD2Uttkj4-FVB5YiaZiTNIJFgCSXOe5CmMrqaqhJVufMXsSpXYRgn8W85bxKgqe0cjbYVRphqFH34uK7ywlOhiQUEDitVaqbnXsszmc5D8IfGczwh) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/Cgvcl13pVp8L4Zswm5dFN06BFAwreykuXqfAl5GT42SdufEDSEw4Dix0GWvDCL6o6ULfXsQ75pb_zcIW_Q5TwQL4o5SZieXOsKN7EOAHZMZtmpoYxnslb4x1QKqyfd6Jn4Tw_05k5K9Cw3rUmsBF1KJ-E3-qBbCj50j_dibKH4sOhEEv0m3fuw-ckKErEnfX) | | | **8**. A compound of Formula VIII:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/1w4HqA8H3AQ0tnQj41358MniFLhaJytZNWF52zHomXaQR1mvGTsOXuz1w1uVRrgJD00chVvbAX6-WvYn9eGrbvHa0CveCJLk5aiFScOAFCkJSX8cUq4bVarC509h-xUqB-ty4VlLDgO-O8KqmYQBP5P2jbv7JAUgRNEgY8Y3Qs3pSLaTO1QU0h38LQsOh8JI) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/O3QkmRuKCqa280y9BuX8M99TApN_swG_f1rDC02ZLikqgyA8zuPeQKunGauZRYlkIb9yxPh5AtzIyZxk4cjthSxr8cNzTZe3ddGgrxE_ohbqlUrwKEPmdjdZUp4rI19GkLAMQRfxibL51F9C2ee6BPcbNDPPWXgb8ZSlNYvuqwtTROTqVVEiRyuTNy25N7Gg)  and a pharmaceutically acceptable hydrate, solvate, prodrug, enantiomer, and stereoisomer thereof; wherein  RH independently represents caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine, furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol, calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone, menaquinones, menadione, menadiol, thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/1f9UhzJT2KJKjNXyRDpNFXvpwrCGKnOSYDCGpXVsQCFYMHFUhm_WZBhNhrxrDqRLzjaIcMmFSVf1HlbRjI-tDYR_WpBc5SGQ8FWeAVsS2IEN82dVil1LEWsOnpudZc_ZUv4iKC4h8pH0rDaoiElGjNROfohiBdan8KA5SQqOb4GF-BRukbJi_4COtUgFOKKC) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/uYmDOzYpmWi0tgus16LAMorsfs78ZnTDegHzuzz2XwAGciAzvlzlsyV1LdC029Z1hiW2VQYUblaEbq6RHRwCVlwSJ35ORoXAMWl5epSoCcKjYiW89DFS0wg39A0zB9Husr2TYizbDmKCLKW6Vw756EBa1YjFnHO6iwnOTNCUjuZ0yeRtAoOSp0WbvSRkpYyJ)  wherein, within the proviso R 1, R 2and R 3independently represent   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/dJYVlmHj5BygaQJni-YW_cjtz-vteiOXecu4mirb_IiOWnC2Na46aoSPkHI7XGpLSfKAYJ-Rl3VQipG3p6LJiY8b4JAsgtwzDVhr9NP7eAB1_e5XEZtc86cx2jZMM_Wa0evklhVTFEqWqY_wR_dE3vqoeX3qlNyTkxtRWH61Tlq7IxOlLZz8ZxG50bFUzyIn) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/6i03qcIo1CwLShZD3jvGJGF5So8dM4GQphf6C5LU2WE3gsx0u3v-ulpE58UsWDnhYrQjnyWPCWS7jMLM63AhfEhoKLIpdV7Sjmdf_PHR0N0jyBgWUZJF83kAQoLQ8nPwHfT2_C-K_Oh878LvwbO84ClLqEPboF2lUBZMyidU5p8Hj3hjiJKhDTIbtNHpmcFc) | | | **9**- **21**. (canceled) | | | **22**. A pharmaceutical composition comprising a compound of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00007) and a pharmaceutically acceptable carrier. | | | **23**. A pharmaceutical composition comprising a compound of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00008) and a pharmaceutically acceptable carrier. | | | **24**- **36**. (canceled) | | | **37**. The pharmaceutical composition of [**claim 22**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00022), wherein said pharmaceutical composition is formulated to treat a patient with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | | **38**. The pharmaceutical composition of [**claim 23**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00023), wherein said pharmaceutical composition is formulated to treat a patient with an effective amount of said pharmaceutical composition by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. | | | **39**- **51**. (canceled) | | | **52**. The pharmaceutical compositions of [**claim 37**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00037), wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | | **53**. The pharmaceutical compositions of [**claim 38**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00038), wherein said pharmaceutical composition is formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | | **54**- **64**. (canceled) | | | **65**. A compound of [**claim 7**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00007), wherein formula VII is selected from a group consisting of   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/w0NgiN1_CAj-L8FfvM0t5CBFR5f-ZNm-f84UV3Ij3wQN89dr-wCSZglnv5xLpawdkNHIvHGUc4G-ODQjEqFd8aKqAZ4TdCFYIn8lWyPzpFULXRwK20saqf-LjA2RErCwH28Q84UtimxRpUa1th7QCOO3X7zRqlLbTuVe8ObtXpEzSjvf8wFd3vwu82hBhv4G) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/2k3vjqLOuagso6Gb8mS7po6fSCvbVt8sZD4x6XuVj0M99_I8JJcNEZP9j2tE4Ju_Ew_kfiE5KLhzG_P3xTjK2TpaqiSLP2hORaDErk1PUVryF1tF-byZsbcsdsN2g3z6Ig8SY1b14jjEMF9cQqYm7adM4iMbkoB06qkuVobITXvYgJXwENvWFkGJfqKAnx9o) | | | **66**. A pharmaceutical composition comprising a compound of [**claim 65**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00065), and a pharmaceutically acceptable carrier. | | | **67**. The pharmaceutical composition of [**claim 66**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00066), wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. | | | **68**. The pharmaceutical composition of [**claim 67**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00067) formulated of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | | **69**. A compound of [**claim 8**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00008), wherein formula VIII comprises   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/jZ9UhvsIJ_zluc8TRAjt0ZVvDpjR5kU-thLBFvMjBxBfw3l-ewnqdJwfT0zh8JnPljj8u9wkQYdNzX9RtPL8Ahi833ci0SkDq_GkHI4zZ4ecLsSF_raqyv6EX9ZSXJTiBqGe4f2-cbVq4a5jyZuK7Qej00vMes93_8IH1Z44EjmHuaHMIC4Qa7WcC57zQz9q) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US356971763/file/mq8VGFfZRZqo_rzIkBXUojF7dWKSfOLTyMZH3FIkvHcA-36NutG7_8UMa_gAP7_L-cE16UCdUoSJhx_ugUiKH61f37_dqe88NLeAWVWfF7oibfIehPet9hMgzWJS-tngN-BfPXWctGhkPxtQPhJ2aqUo-lpw0KXf2CBOB3sQLf5-kPmSDYFzxt4cO8TF25Nz) | | | **70**. A pharmaceutical composition comprising a compound of [**claim 69**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00069), and a pharmaceutically acceptable carrier. | | | **71**. The pharmaceutical composition of [**claim 70**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00070), wherein said pharmaceutical composition is formulated to treat a patient in need with an effective amount administering the patient in need by oral administration, delayed release, sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration, or transdermal administration. | | | **72**. The pharmaceutical composition of [**claim 71**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US356971763&_cid=P12-L970NS-86646-3#CLM-00071) formulated of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain. | | | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, or parenteral administration, or as a lozenge, spray, oral solution, buccal mucosal layer tablet, syrup or injection. Such compositions may be used to treat chronic pain. |  |
| 23 | **US20220096467** | 2022 |  | |  | | --- | | **1**. A pharmaceutical compositions comprising physical mixture of:  a. a therapeutically effective amount of a selective alpha-adrenergic receptor agonist, or a pharmaceutically acceptable salt, a stereoisomer or an enantiomer thereof; and  b. a therapeutically effective amount of lipoic acid, or a pharmaceutically acceptable salt, stereoisomer or an enantiomer thereof. | | **2**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the selective alpha-adrenergic receptor agonist agent is selected from a compound of Formula II:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/4hxIy_vfMnlxPbQdZny2qqUNLVCzcnFi_lbA1Y_LyznZNAI00BwsFk4ga9yBLM2xmjFtbjlstrEiOjKpKmi4b75h9wIa1gMR8Yqidk0JGMcZFx4aAprZFMEspb5E1X0wT0JQnt7OOZgl2QO07LRciaklTu0aD-X_nNdr5TLe2yZRnRZop5hzCsNCCxYEWY49) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/Wsdj4Sd-5BTuLw80C-2_sBcMVGyb8MuIbUZTOtB3tNEOzCoUOCUQvndldfZCsG3IsQuOudhMYx1kQzVXXjs4ZyZAetDz79vmDPKROx8baAoSy6s91yZH7ntfl4uQBBd7m5Z1ZYqG8dO2QmMs1gEUmRylwMbbqzOq4XcjQvtj5ue95KbCY_bH41qSTrhA6B7X)  or a pharmaceutically acceptable salt or a stereoisomer thereof; and  wherein,  RH is   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/lnLpdtUCW5TfT69F5TbkXs-iV0jfcSmAvVDtfrRHFIT4bpdTNvgzaLS2CIXt9ZinTEfjsiKVYOzwT7_tjsOUMmP1ImwuqD88Dzn8K_fUyfNDS2xlXfHIUlECSwKXw2w7_PxfDO6Fx-sYofw3IEjBnIUscwdexlqedM-sjQ5jSHRIZKbtuDkaX-aKRY04qEeG) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/zPhsB3MEY-ZFnV5Z0rS9jGawf0IPRqtZxUOWU7XFim-h8U6fJbi7HAa7JsWjTbC3Jp14RAMBCNP61V5-prZthcnm9UCnswsIQ472fZqufaoYHtdyoxrkUgVs8GUtg9qM9NQBMNaaihRu6v_mxVwL6kW5td3KyLb8lehCAEQaxZFXBSH2f3ZfV2pVs5DJ2hkb)  tartrate, hydrochloride, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine, furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, elaidic acid, linoleic acid, linolenic acid, linolelaidic acid or arachidonic acid. | | **3**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the selective alpha-adrenergic receptor agonist agent is selected from a compound of Formula (III):   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/ZnJe-KJUmmaHQXyNdSffnDXnvyxPvX4rCi1_uytvpqRuKx-SZDDmDMfcPD_fzEebmBS0Ic7J6aWhTKdhRhZCEGdC6kShRRWmqCAKuvi30BiyBRJFPKtU4_jPuF9AWRjJcvXDOb45YbcTO2TecsPzlm0Y5WC0IOQvMVWfvutyDrDBx3-UA9TKIKLRExDan1iX) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US355910721/file/og6m_XoCKYAxbiQn_QCcPbN6B6qB4r5Bbx-3skNi8Z---FVXz2bsXYPwxVMdxNHfRT_8SGm2mHBVMvVmYGrjuelQjft8QOhEGKkyaGSnJnMMPoeGFfYmSh8DxWoRIlj5Uge2LKLuOlGy1JeCPKeAbh9TTw5s6geArTzgDSZaKDBZAQNtaAFBF8Rzvcr5PmXW)  or a pharmaceutically acceptable salt or a stereoisomer thereof; and  wherein,  RH is as defined in [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00002). | | **4**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the lipoic acid is (R)-(+)-lipoic acid, (S)-(−)-lipoic acid or racemic mixture (R/S)-lipoic. | | **5**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the physical mixture comprises compound of Formula II is brimonidine tartrate and R-(+)-lipoic acid. | | **6**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the physical mixture comprises compound of Formula III is oxymetazoline hydrochloride and R-(+)-lipoic acid. | | **7**. (canceled) | | **8**. (canceled) | | **9**. (canceled) | | **10**. The pharmaceutical composition of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00001), wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. | | **11**. The pharmaceutical compositions as claimed in [**claim 10**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00010), wherein the pharmaceutical composition is formulated as drops, a solution, an emulsion, a paste, a gel, a cream, an ointment, a spray, tablets, effervescent tablets, a mucoadhesive formulation, a subdermal formulation, a transdermal formulation, a hydrogel, injections, or a sustained release formulation for oral, ocular, dermal, parenteral, subdermal, topical and nasal administration. | | **12**. A method of using the pharmaceutical composition of [**claim 11**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00011), for the treatment or alleviation of xerostomia, burning mouth syndrome, dermal disorders and eye diseases or disorders or a complication thereof. | | **13**. The pharmaceutical composition of [**claim 2**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00002), wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. | | **14**. The pharmaceutical compositions as claimed in [**claim 13**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00013), wherein the pharmaceutical composition is formulated as drops, a solution, an emulsion, a paste, a gel, a cream, an ointment, a spray, tablets, effervescent tablets, a mucoadhesive formulation, a subdermal formulation, a transdermal formulation, a hydrogel, injections, or a sustained release formulation for oral, ocular, dermal, parenteral, subdermal, topical and nasal administration. | | **15**. A method of using the pharmaceutical composition of [**claim 14**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00014), for the treatment or alleviation of xerostomia, burning mouth syndrome, dermal disorders and eye diseases or disorders or a complication thereof. | | **16**. The pharmaceutical composition of [**claim 3**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00003), wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. | | **17**. The pharmaceutical compositions as claimed in [**claim 16**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00016), wherein the pharmaceutical composition is formulated as drops, a solution, an emulsion, a paste, a gel, a cream, an ointment, a spray, tablets, effervescent tablets, a mucoadhesive formulation, a subdermal formulation, a transdermal formulation, a hydrogel, injections, or a sustained release formulation for oral, ocular, dermal, parenteral, subdermal, topical and nasal administration. | | **18**. A method of using the pharmaceutical composition of [**claim 17**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00017), for the treatment or alleviation of xerostomia, burning mouth syndrome, dermal disorders and eye diseases or disorders or a complication thereof. | | **19**. The pharmaceutical composition of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00005), wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. | | **20**. The pharmaceutical compositions as claimed in [**claim 19**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00019), wherein the pharmaceutical composition is formulated as drops, a solution, an emulsion, a paste, a gel, a cream, an ointment, a spray, tablets, effervescent tablets, a mucoadhesive formulation, a subdermal formulation, a transdermal formulation, a hydrogel, injections, or a sustained release formulation for oral, ocular, dermal, parenteral, subdermal, topical and nasal administration. | | **21**. A method of using the pharmaceutical composition of [**claim 20**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00020), for the treatment or alleviation of xerostomia, burning mouth syndrome, dermal disorders and eye diseases or disorders or a complication thereof. | | **22**. The pharmaceutical composition of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00006), wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient. | | **23**. The pharmaceutical compositions as claimed in [**claim 22**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00022), wherein the pharmaceutical composition is formulated as drops, a solution, an emulsion, a paste, a gel, a cream, an ointment, a spray, tablets, effervescent tablets, a mucoadhesive formulation, a subdermal formulation, a transdermal formulation, a hydrogel, injections, or a sustained release formulation for oral, ocular, dermal, parenteral, subdermal, topical and nasal administration. | | **24**. A method of using the pharmaceutical composition of [**claim 23**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US355910721&_cid=P12-L970NS-86646-3#CLM-00023), for the treatment or alleviation of xerostomia, burning mouth syndrome, dermal disorders and eye diseases or disorders or a complication thereof. | | treatment or alleviation of xerostomia, dermal diseases and eye disorders. |  |
| 24 | **AU2022201457** | 2022 |  | 1.   A compound of Formula I:    Formula I  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula II  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof; Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        3.    A compound of Formula III:    Formula III  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein,    within   the  proviso     R,    R2,  R3 independently    represents      4.    A compound of Formula IV:    Formula IV  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula V  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin A, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7 dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25 dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula VI  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  [00171]               Wherein,  RH independently represents  phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin A, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7 dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25 dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or  wherein,  within   the  proviso     R,    R2,  R3 independently    represents      7.    A compound of Formula VII:    Formula VII  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, , 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        8.    A compound of Formula VIII:    Formula VIII  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH  independently     represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, , 1-docosanol or    wherein, within the proviso R, R2 , R3 independently represents    9.   A compound of Formula IX:    Formula IX  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula X  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula XI  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula XII  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        Formula XIII  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene j-carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein,    within   the  proviso     R,    R2,  R3 independently    represents      14.  A compound of Formula XIV:    Formula XIV  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  R', R2, R3 independently represents        RH independently represents  oxytetracycline, tetracycline, amphenicol, chloramphenicol, neomycin, gentamicin, amikacin, nadifloxacin, virginiamycin, rifaximin, fusidic acid, bacitracin, tyrothricin, mupirocin, sulfonamides, silver, sulfadiazine, sulfathiazole, mafenide, sulfamethizole, sulfanilamide, sulfamerazine, aciclovir, penciclovir, idoxuridine, edoxudine, imiquimod, resiquimod, podophyllotoxin, docosanol, tromantadine, inosine, lysozyme, ibacitabine, lysine, ingenol mebutate, metronidazole, acyclovir, phenol, valaciclovir, valacyclovir, famciclovir, silver, zinc, iodine, benzalkonium, benzethonium, cetylpyridinium, clioquinol, triclosan, chlorhexidine, chloramphenicol, menthol, neomycin, gentamicin, amikacin, ketamine, esketamine, arketamine, ceftriaxone or cefepime.  15.  A compound of Formula XV:    Formula    XV  and pharmaceutically acceptable hydrates, solvates, prodrugs, enantiomers, and stereoisomers thereof;  Wherein,  RH independently represents  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor 10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid , glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5 disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caproic acid, caprilic acid, capric acid, lauric acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, phospholipids, phosphatidylcholine, oleic acid, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, phospholipids, phosphatidylcholine, menthol, retinoic acid, vitamin a, retinol, retinal, isotretinoin, curcumin, tretinoin, u-carotene -carotene retinol, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (kl), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, ascorbic acid, dehydroascorbic acid, 1-docosanol or    wherein, within the proviso R, R2, R3 independently represents        16.     A Pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.  17.     A Pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.  18.     A Pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.  19.     A Pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.  20.     A Pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.  21.     A Pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable carrier.  22.     A Pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.  23.     A Pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable carrier.  24.     A Pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable carrier.  25.     A Pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.  26.     A Pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable carrier.  27.     A Pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.  28.     A Pharmaceutical composition comprising a compound of claim 13 and a pharmaceutically acceptable carrier.  29.     A Pharmaceutical composition comprising a compound of claim 14 and a pharmaceutically acceptable carrier.  30.     A Pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.  31.     The pharmaceutical composition of claim 16, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  32.      The pharmaceutical composition of claim 17, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  33.      The pharmaceutical composition of claim 18, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  34.      The pharmaceutical composition of claim 19, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  35.      The pharmaceutical composition of claim 20, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  36.      The pharmaceutical composition of claim 21, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  37.      The pharmaceutical composition of claim 22, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  38.      The pharmaceutical composition of claim 23, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  39.      The pharmaceutical composition of claim 24, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  40.      The pharmaceutical composition of claim 25, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  41.      The pharmaceutical composition of claim 26, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  42.      The pharmaceutical composition of claim 27, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  43.      The pharmaceutical composition of claim 28, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  44.      The pharmaceutical composition of claim 29, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  45.      The pharmaceutical composition of claim 30, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.  46.      Compounds and compositions of claim 31 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  47.      Compounds and compositions of claim 32 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  48.      Compounds and compositions of claim 33 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  49.      Compounds and compositions of claim 34 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  50.      Compounds and compositions of claim 35 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  51.      Compounds and compositions of claim 36 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  52.      Compounds and compositions of claim 37 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  53.      Compounds and compositions of claim 38 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  54.      Compounds and compositions of claim 39 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  55.      Compounds and compositions of claim 40 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  56.      Compounds and compositions of claim 41 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  57.      Compounds and compositions of claim 42 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  58.      Compounds and compositions of claim 43 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  59.      Compounds and compositions of claim 44 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  60.      Compounds and compositions of claim 45 are formulated for the treatment of chronic pain, surgery pain, wound pain, ulcer pain, neuropathic pain, central and peripheral nerve damage pain.  61.      A compound of claim 4, comprising of formula IV:    62.         A compound of claim 6, comprising of formula VI:    63.         A compound of claim 5, comprising of formula V:    64.         A compound of claim 14, comprising of formula XIV: | Treatment of Chronic Pain |  |
| 25 | **BR112022001659** | 2022 |  |  | composition for treating disorders affecting the anus and the rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermal administration, spraying, injection or other formulation known in the art. |  |
| 26 | **IN202247006765** | 2022 |  |  | treating disorder affecting the anus and rectum. |  |
| 27 | **AU2022201182** | 2022 |  | 1.   A compound of Formula II:    Formula II  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH is    wherein,  each Ri, R2 and R 3 independently represents      O    2. A compound of claim 1, wherein the compound has the chemical structure of:    3. A pharmaceutical composition comprising a compound according to claims 1 or 2 and a pharmaceutically acceptable carrier.  4. The pharmaceutical composition of claim 3, wherein said pharmaceutical composition is formulated with an effective amount of compound of claim 1 or 2 for oral administration, transmucosal administration, topical administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration.  5. The pharmaceutical composition of claim 3 or 4, which is formulated for the treatment of a fungal infection, a candidiasis infection, and/or an oral infectious disease, or any combination thereof.  6.          A method of treating an infection in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of the compound according to any one of claims 1 or 2; and/or the pharmaceutical composition according to any one of claims 3-5; wherein the infection is a fungal infection, a candidiasis infection, and/or a fungal oral infectious disease, or any combination thereof.  7.          Use of a compound according to any one of claims 1 or 2, and/or a pharmaceutical composition according to any one of claims 3-5, in the manufacture of a medicament for the treatment of a fungal infection, a candidiasis infection, and/or a fungal oral infectious disease, or any combination thereof.  8.          A compound according to any one of claims 1 or 2, or a pharmaceutical composition according to any one of claims 3-5, for use in treating a fungal infection, a candidiasis infection, and/or a fungal oral infectious disease, or any combination thereof. | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 28 | **AU2022201181** | 2022 |  | 1.   A compound of Formula X:    Formula X  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein, ~0  0  RH represents    wherein,  each R1, R2 and R3 independently represents        2. A compound of claim 1, wherein the compound has the chemical structure of:    3. A pharmaceutical composition comprising a compound according to any one of claims 1 or 2 and a pharmaceutically acceptable carrier.  4.          The pharmaceutical composition of claim 3, wherein said pharmaceutical composition is formulated with an effective amount of compound of claim 1 or claim 2 for oral administration, transmucosal administration, parenteral administration, intravenous administration, subdermal administration, rectal administration, buccal administration or transdermal administration.  5.          The pharmaceutical composition of claim 3 or 4, which is formulated for the treatment of fungal infections, a candidiasis infection, and/or an oral infectious disease.  6.          A method of treating an infection in a patient in need thereof, the method comprising the step of administering to the patient an effective amount of the compound according to any one of claims 1 or 2; and/or the pharmaceutical composition according to any one of claims 3-5; wherein the infection is one or more selected from the group consisting of a fungal infection, a candidiasis infection, and an oral infectious disease, and any combination thereof.  7.          Use of a compound according to any one of claims 1 or 2, and/or a pharmaceutical composition according to any one of claims 3-5, in the manufacture of a medicament for the treatment of a fungal infection, a candidiasis infection, and/or an oral infectious disease.  8.          A compound according to any one of claims 1 or 2, or a pharmaceutical composition according to any one of claims 3-5, for use in treating a fungal infection, a candidiasis infection, and/or an oral infectious disease, and any combination thereof | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 29 | **WO2022049462** | 2022 |  | I Claim:  1. A process for producing compound of formula I, comprising:    Formula I  a) preparing of 2-propylpentanoyl chloride;  b) condensation of 2’,3’-Di-O-Acetyl-5’-deoxy-5-fluorocytidine with propylpentanoyl chloride from step a) to obtain compound of formula I; and  c) compound of formula I obtained from step b) is subjected to purification of the compound of formula I in presence of the suitable organic solvents.  2. The process according to claim 1, wherein the 2-propylpentanoyl chloride of step a) is prepared by reacting the ice cold stirred solution of 2-propylpentanoic acid in organic solvent with oxalyl chloride.  3. The process according to claim 1, wherein the condensation reaction of step b) comprises adding 2-propylpentanoyl chloride to a reaction mixture comprising 2’,3’-Di-O-Acetyl-5’- deoxy-5-fluorocytidine suspended in an organic solvent with a suitable base and in presence of an N- acylation catalyst to form compound of formula I, further the compound of formula I is extracted in step wise manner.  4. The process according to claim 3, wherein the compound of formula I is extracted from the condensation reaction mixture by first charging with water resulting in formation of a upper aqueous and a bottom organic layer.  5. The process according to claim 3 wherein the organic layer is separated, from the aqueous layer and sequentially washed with water, HCl, and saturated aqueous sodium bicarbonate solution and brine and further dried, filtered and distilled to extract compound of formula I.  6. The process according to claim 5 wherein the extract compound of formula I is dissolved in heptane and filtered and washed again with heptane further dried under vacuum to obtain purified form of compound of formula I.  7. The process according to claim 1, catalyst used for the condensation reaction is N-acylation catalyst wherein the N-acylation catalyst is selected from 4-dimethylaminopyridine, diisopropylamine, 1-hydroxybenzotriazole, 2-pyridone, 1,4-diazabicyclo[2.2.2]octane, 1,8- diazabicylco [5.4.0]undec-7-ene, and 2,6-lutidine, 4-pyrrolidinopyridine, 2-hydroxypyridine, tributylphosphine, 1-methylimidazole, Aluminum chloride, Iron chloride, Galium trichloride, Antimony pentachloride, Zinc Chloride, Stannous chloride, Aluminum Bromide, Iron Bromide, Stannic chloride, Gallium tribromide, Hydrogen Flouride, Boron trifluoride, trimethylsilyl trifluoromethane sulfonate, platinum, palladium, or rhodium in concentrated sulfuric acid, or a mixture thereof.  8. The process according to claim 3, wherein the bases is selected from organic bases such as Organolithiums, Grignard reagents, Amines, trimethylamine (TEA), N-heterocyclic compounds, Tetra alkylammonium compounds and phosphonium hydroxides, Metal alkoxides and amides and metal silanoates such as n-butyllithium, sec-butyllithium, tert- butyllithium, hexyllithium, isopropyllithium, butylmagnesium chloride, isopropylmagnesium chloride, propylmagnesium chloride, sec-butylmagnesium chloride solution, tert- butylmagnesium chloride, 2-tert-butyl-1,1,3,3-tetramethylguanidine, ethylmagnesium bromide, ethylmagnesium chloride, hexylmagnesiumchloride, isobutylmagnesiumchloride, 2,2,6,6-Tetramethylpiperidine, 4-(dimethylamino)pyridine, N,N diisopropylmethylamine, diethylamine, Morpholine, Piperidine, (Piperidinomethyl)polystyrene,4- (Dimethylamino)pyridin, N-Ethyldiisopropylamine, Lithium tert-butoxide , Barium tert- butoxide , Magnesium di-tert-butoxide, Magnesiumethoxide, Potassiumethoxide, Sodium tert-butoxide, Tetrabutylammonium hydroxide, Tetramethylammonium hydroxide solution, Trimethylphenylammonium hydroxide, Tetrapropylammoniumhydroxide ,Tetrahexylammonium hydroxide solution , Sodium tert-pentoxide, Sodium ethoxide, Sodium tert-butoxide, Potassium tert-butoxide,Lithiumisopropoxide Lithiumethoxide,Lithium tert- butoxide, Barium tert-butoxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and similar lithium, potassium, calcium, magnesium, barium compounds, diisopropyl ethylamine or mixtures thereof.  9. The process according to claim 3, wherein the organic solvent is selected from polar aprotic solvents, dimethyl formamide, dimethyl sulfoxide, N-methylpyrrolidinone, ethereal solvents, tetrahydrofuran, 2-methyl tetrahydrofuran, methyl t-butyl ether, dimethyl ether, diisopopyl ether, methyl tert butyl ether 1,4-dioxne and diethoxymethane, hydrocarbons, benzene, toluene, hexanes, xylene, heptane, halogenated solvents, dichloromethane, chloroform, carbon tetrachloride, trichloroethane, 1,2-dichloroethane, benzotrifluoride, acetates, ethyl acetate, isopropyl acetate, butyl acetate, acetonitrile, methyl vinyl ketone, N,N- dimethylacetamide, t-butyl methyl ether, petroleum ether, diethyl ether; water-soluble alcohols, butanol, methanol, ethanol, isopropanol, biphasic solvent systems or mixtures thereof.  10. The process according to any of the proceeding claims, wherein the compound of formula I obtained is substantially free of all impurities.  11. Compound of formula I prepared by the process according to the preceding claims can be used in preparation of medicament for treating or preventing cancers. | suspending or dissolving the crude in an appropriate solvent, removing the insoluble matter by filtration, and condensing the filtrate. The process is useful for producing (2R, 3R, 4R, 5R)-2-(5-fluoro-2-oxo-4-(2-propylpentanamido)pyrimidin-1-(2H)-yl)-5-methyl tetrahydrofuran-3,4-diyl diacetate with high yield and purity % through a simple procedure. |  |
| 30 | **NZ785776** | 2022 |  |  | formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 30 | **NZ785776** |  |  |  | treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain. |  |
| 31 | **WO2022043902** | 2022 |  | M:  A process for producing compound of formula I, comprising:    Formula 1  a) condensation reaction of 2’,3’-di-O-acetyl-5’-deoxy-5-fluorocytidine with octanoyl chloride reagent to obtain compound of formula I; and  b) compound of formula I obtained from step a) is subjected to purification.  The process according to claim 1, wherein the condensation reaction is carried out in the presence of an N-acylation catalyst or condensation catalyst.  The process according to claim 2, wherein the N-acylation catalyst is selected from 4-dimethylaminopyridine, diisopropylamine, 1 -hydroxybenzotriazole, 2-pyridone, 1,4-diazabicyclo[2.2.2]octane, 1,8-diazabicylco [5.4.0]undec-7-ene, 2,6-lutidine, 4-pyrrolidinopyridine, 2-hydroxypyridine, tributylphosphine, 1- methylimidazole, aluminum chloride, iron chloride, galium trichloride, antimony pentachloride, zinc chloride, stannous chloride, aluminum bromide, iron bromide, stannic chloride, gallium tribromide, hydrogen fluoride, boron trifluoride, trimethylsilyl trifluoromethane sulfonate, platinum, palladium, or rhodium in concentrated sulfuric acid or mixtures thereof..  The process according to claim 1, wherein the condensation reaction is carried out in the presence of an organic base.  The process according to claim 4, wherein the organic bases is selected from diisopropyl ethylamine, organolithiums, Grignard reagents, amines, trimethylamine, N-heterocyclic compounds, tetra alkylammonium compounds, phosphonium hydroxides, metal alkoxides, amides, metal silanoates, n butyllithium, sec -butyllithium, tert-butyllithium, hexyllithium, isopropyllithium, butylmagnesium chloride, isopropylmagnesium chloride, propylmagnesium chloride, sec-butylmagnesium chloride solution, tert butylmagnesium chloride, 2-tert-butyl-1,1,3,3-tetramethylguanidine, ethylmagnesium bromide, ethylmagnesium chloride, hexylmagnesiumchloride, isobutylmagnesiumchloride, 2,2,6,6-tetramethylpiperidine, 4 (dimethylamino )pyridine, N,N diisopropylmethylamine, diethylamine, morpholine, piperidine, (piperidinomethyl)polystyrene,4 (dimethylamino)pyridin, N-ethyldiisopropylamine, lithium tert-butoxide, barium tert-butoxide, magnesium di-tert-butoxide, magnesiumethoxide, potassiumethoxide, sodium tert-butoxide, tetrabutylammonium hydroxide, tetramethylammonium hydroxide solution, trimethylphenylammonium hydroxide, tetrapropylammoniumhydroxide, tetrahexylammonium hydroxide solution, sodium tert-pentoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, lithiumisopropoxide, lithiumethoxide, lithium tert butoxide, barium tert-butoxide, sodium hydroxide, sodium carbonate, sodium bicarbonate, sodium methoxide and similar lithium, potassium, calcium, magnesium, barium compound or mixtures thereof.  The process according to claim 1, wherein the condensation reaction is carried out in the presence of an organic solvent.  The process according to claim 6, wherein the organic solvent is selected from polar aprotic solvents, dichloromethane, dimethyl formamide, dimethyl sulfoxide, N-methylpyrrolidinone; ethereal, tetrahydrofuran, 2-methyl tetrahydrofuran, methyl t-butyl ether, dimethyl ether, diisopopyl ether, methyl tert butyl ether 1,4-dioxne, diethoxymethane, hydrocarbons, benzene, toluene, hexanes, xylene, heptane, halogenated solvents, dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane, acetates, ethyl acetate, isopropyl acetate, butyl acetate, acetonitrile, methyl vinyl ketone, N,N-dimethylacetamide or mixtures thereof.  The process according to claim 1, wherein the condensation reaction is carried out at temperatures -50° C to about 150° C or -25° C to about 100° C or 0° C to 50° C.  The process according to claim 1, wherein the condensation reaction mixture of step a) is charged with water resulting in formation of upper aqueous layer and the bottom organic layer. The process according to claim 9, wherein the upper aqueous and lower organic layer are extracted separately using extraction solvent.  The process according to claim 10, wherein the extraction solvent is selected from a water, HC1, NaOH, DCM or citric acid.  The process according to claim 10, wherein the lower organic layer is combined with water followed by treating with aqueous sodium bicarbonate and sodium chloride solution and distilled to obtain compound of formula I.  The process according to claim 12, wherein the compound of formula I is dissolved and washed with organic solvent and further purified by filtration, evaporation and crystallization. The process according to claim 13, wherein the compound of formula I obtained is substantially free of all impurities.  Compound of formula I prepared by the process according to the preceding claims can be used in preparation of medicament for treating or preventing cancers. | The process is useful for producing (2R, 3R, 4R, 5R)-2-(5-fluoro-4-octanamido-2-oxopyrimidin-1(2H)-yl)-5-methyltetrahydrofuran-3, 4-diyl diacetate with high yield and purity % through a simple procedure. |  |
| 32 | **IL290150** | 2022 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN |  |
| 33 | **IL290151** | 2022 |  |  | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANAL AND RECTAL DISORDERS |  |
| 34 | **NZ785289** | 2022 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 35 | **NZ785293** | 2022 |  |  | treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. |  |
| 36 | **SG11202200731R** | 2022 |  |  | COMPOSITION AND METHODS FOR THE TREATMENT OF ANAL AND RECTAL DISORDERS |  |
| 37 | **US20220048850** | 2022 |  | |  | | --- | | **1**. A compound of Formula I:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/8bLzGhnEyCR-pAL2Ibmz8thWfTpAFJGU7RWtli_DweP8zbzp7ju2jBP2ckVgVMtGyyDXCZOs104xBwhT2JPXscuHdxGasY5Zz40muyZezTA0aEoNvcF9519W2jgQVJRcxnXL6Yxv9C62KJOrdztWws1aIPw0QE-0vwqwn_McYaiAkuLvPui0aQ0nOuRsW277) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/ZNcULbjxxaLIpbzEfupDLXro1BUYoeYKuQunaA253QeJMgmW6QWDZ4IB4iXjXo67E2UEsoBstw3teMwWSW3fxp4wyvVRYphAtGf-S8eVD2gcPKDV95SlsUNRu5tiJ4UTLfGNHEwr54RKHrWha7oY6jsxxcFuo8cyfaIPBs3xTs0RHsuavme8nZJm2fAWxCf3)  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/XXAx-UpCOKJtaEPe8wT0kOyGYeNtJmEW6-e8f_uTjFPvXD62Vxa-qPjaitkKfPxHBOxhhTZrDzpv6VcZ6N_YiGdVEj1DA4uW1KB8DvwE34NisvRxGOSopYPywbVkcPhSkY3bP7fIRDtQcuqY4UEs-AhM7JdfWRZZY2OYbIviP1Bs5beZgsZbsS7XAOBsmTcq) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/46MiSqmPasB65v3XEiBHyau5XuDVRNGYUgZm85Of_Jx3y_e39jERHWx9Bm3HyVKAy0jOdP1E-De6ZGlzRm4W2TR_uTyXaLlq00bFoUd3322G04YG-GH74UXIQMdeGQiuQabWINapDjSuJmfa1LW0iIdT1DBHqoqcGmZKmY15FYFFWLorYoJNQpHobFrnN3ZX)  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, alpha linoleic acid, alpha linolenic acid, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, phospholipids, phosphatidylcholine, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, dehydroascorbic acid or 1-docosanol. | | **2**.- **4**. (canceled) | | **5**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00001) and a pharmaceutically acceptable carrier. | | **6**. The pharmaceutical composition of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00005), wherein said pharmaceutical composition is formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral admiration, buccal admiration, rectal admiration, topical admiration, transdermal admiration, transmucosal admiration, lozenge, spray, intravenous admiration, oral solution, nasal spray, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. | | **7**. The pharmaceutical compositions of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00006), wherein said pharmaceutical compositions are formulated for the treatment of eye disorders and skin diseases. | | **8**.- **16**. (canceled) | | **17**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00001), wherein said compound is selected from the group consisting of   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/qPX08rleHqyZy9mPi5UZ1guyBD4GodeU6RAAGNwQQlYu79ZEQXMVDd9RqZYG8a79eumuLMOehCYUWdyi2YRUS2u9B5Y1s5RdoOZn9IeguWZLw7Td17J-nlG1JdBPgaWq5g244wM8dMPPWSojiU0mHH562o01dsc2ANr9lVDsxsSgVpuhNsb6uIJ0PW-K61Jh) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/cGh0WQGeGdK3FLdZQ7Z5nYFT8GDTk6zS5GGoqH5GZjqP3Aw8dzAR-xo0AhPBOFYVFuaUJNAm6L9qckD57HZzi7lOmRU6-zYo8Y-wl235hzlT12k16AplbG6hqjjf6twaSuhNrn3MDZniYdZM3U_mmiMMTZ8BS3MruN7_qMUaqHHzA3RcSetMg_iKZpH5ccl9) | | **18**. A pharmaceutical composition comprising a compound of [**claim 17**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00017) and a pharmaceutically acceptable carrier. | | **19**. The pharmaceutical composition of [**claim 18**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00018), wherein said pharmaceutical composition is formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral admiration, buccal admiration, rectal admiration, topical admiration, transdermal admiration, transmucosal admiration, lozenge, spray, intravenous admiration, oral solution, nasal spray, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. | | **20**. The pharmaceutical compositions of [**claim 19**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00019), wherein said pharmaceutical compositions are formulated for the treatment of eye disorders and skin diseases. | | he pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications. |  |
| 38 | **US20220033360** | 2022 |  | |  | | --- | | **1**. A compound of Formula I:   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/hnCT8XjkZ9XtVpvIF22v1yAXBoRTSPrDJ2fy_b5zJjRi72uhv23oAsBRSYxkgF6bK-caP0UcrD46yf4EUvBkwjhB6fExnU8JUIrg1HJCVg9dtFncjCJEgIQ5jJ1GXp6PEi6-XzcX1x_7pPdNfsEodjxqVtFSf8Wwz3UoBV12Wx_IF46EXF5OzReKV13w8ipZ) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/pFPbgy74kyBQCDPQY8nUQOnD7mCZHu5p2zdCiyE7uq50JcSvt_DJ0jtb3pbFLpSvuu7oBBHVl9h_Nu8_pA558u7WLUC0As1fqUNEMvxpx9rCa1I5OeW453WBS9NxA9xDbuYmnyHwUFJZ9yue-mEkvU0ZgalHrAWFFZKaG_duIxC1Snp1Mo3YvcH9mGyVEAMH)  and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof;  wherein,  RH independently represents   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/r4G2oxT9xQum28VtfrEECvcsTqTJ3L3q28TucKwbuT3ZezkVQl2IIZeCQRbwPi0sruE81_eRBDXfsyabCz15yQpmH1FQx4O50JLeHzSgMa5xMebL0DzjMO75lDIzlzhlgNtK3E4iGuB9EZqajUHKhbKAPCQwdFOmFWrMMdCuuUHAUsf6Tkvvo1MC64IqrA3z) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/dRGFr0B77TvmH-DO_7FrkLTfRdxUS0-JQzdUDuvx-e3hhzmAngyxERqRGYUtNU16Sp18c4MDnnstoEk7lifLg2v91hHbhTtmLq6WOpzc_LUYyg3Tlr8M60cXwb12kJH99JRLBKrwJivny33Ij2BvtgPvb-h53WX5hGVwDCA_gGiFmv91WQiqMSIJp1jS4m3Y)  caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, proprionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega 3 fatty acids, alpha linoleic acid, alpha linolenic acid, omega 6 fatty acids, n-acetyl cysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprilic acid, alpha lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitoleic acid, phospholipids, phosphatidylcholine, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linolelaidic acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene β-carotene, d2 ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitroic acid, d4 dihydroergocalciferol, alfacalcidol, dihydrotachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinones (k2), menadione (k3), menadiol (k4), thiamine, acefurtiamine, allithiamine, benfotiamine, fursultiamine, octotiamine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin, cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, dehydroascorbic acid or 1-docosanol. | | **2**.- **4**. (canceled) | | **5**. A pharmaceutical composition comprising a compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00001) and a pharmaceutically acceptable carrier. | | **6**. The pharmaceutical composition of [**claim 5**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00005), wherein said pharmaceutical composition is formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral admiration, buccal admiration, rectal admiration, topical admiration, transdermal admiration, transmucosal admiration, lozenge, spray, intravenous admiration, oral solution, nasal spray, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. | | **7**. The pharmaceutical compositions of [**claim 6**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00006), wherein said pharmaceutical compositions are formulated for the treatment of eye disorders and skin diseases. | | **8**.- **16**. (canceled) | | **17**. A compound of [**claim 1**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00001), wherein said compound is selected from the group consisting of   [(MOL)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/J8qumTLq_faVzarsNpyWTyR__13jbzG1u1uRaY2nzjyCbVOWdSxACCtBfuDDt6-Be1p5PkvxUwIjwvp6fPifuBysUgP3TYPTZiYd5UMXKD0Fjq_BPa0sfDNdjvWNLXSkQYgoHWXLbPgp-5h5ToVXdNWPUl2eJVlKn0_gMAXNs34pRqJXaI4KYuAyhI5VcXiY) [(CDX)](https://patentscope.wipo.int/search/docs2/nat/US349427847/file/uxNx_hPV_ESg0eiKAy0HO2cTwz57L-Z97M_rN27jOck1HUxAzw0CM5O6tsHqwEqr9DDB3vFYlhdohthtfVj3rJPROYr5FMABC7eST-Jk_ljHG-MLlVomcm_lEvtJNlLu4sF4jrD2jKHPzzWG0xObi3U3tXVqMGdg_I-z8_Xf98FpRM2qgdA00w0LitP8XyRJ) | | **18**. A pharmaceutical composition comprising a compound of [**claim 17**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00017) and a pharmaceutically acceptable carrier. | | **19**. The pharmaceutical composition of [**claim 18**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00018), wherein said pharmaceutical composition is formulated for topical eye drop, topical paste, ocular solution, device-drug delivery, oral admiration, buccal admiration, rectal admiration, topical admiration, transdermal admiration, transmucosal admiration, lozenge, spray, intravenous admiration, oral solution, nasal spray, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. | | **20**. The pharmaceutical compositions of [**claim 19**](https://patentscope.wipo.int/search/en/detail.jsf?docId=US349427847&_cid=P12-L98MDE-63513-4#CLM-00019), wherein said pharmaceutical compositions are formulated for the treatment of eye disorders and skin diseases. | | treatment of eye disorders and skin diseases and may be formulated for the topical eye drop, topical paste, ocular solution, device-drug delivery, oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, cream, dermal ointment, gels, lotions, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. |  |
| 39 | **NZ784603** | 2022 |  |  | for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermaladministration, spray, injection or other known formulation in the art. |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |